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Abstract
A Very Early Rehabilitation Trial after stroke (AVERT):
a Phase III, multicentre, randomised controlled trial
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Julie Bernhardt5,6 on behalf of the AVERT triallists’ collaboration
1Academic Section of Geriatric Medicine, Institute of Cardiovascular and Medical Sciences,
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2Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
3Institute for Ageing and Health, Medical School, Newcastle University, Newcastle upon Tyne, UK
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6University of Melbourne, Parkville, VIC, Australia
*Corresponding author Peter.Langhorne@glasgow.ac.uk
Background: Mobilising patients early after stroke [early mobilisation (EM)] is thought to contribute to the
beneficial effects of stroke unit care but it is poorly defined and lacks direct evidence of benefit.
Objectives: We assessed the effectiveness of frequent higher dose very early mobilisation (VEM) after stroke.
Design: We conducted a parallel-group, single-blind, prospective randomised controlled trial with blinded
end-point assessment using a web-based computer-generated stratified randomisation.
Setting: The trial took place in 56 acute stroke units in five countries.
Participants: We included adult patients with a first or recurrent stroke who met physiological
inclusion criteria.
Interventions: Patients received either usual stroke unit care (UC) or UC plus VEM commencing within
24 hours of stroke.
Main outcome measures: The primary outcome was good recovery [modified Rankin scale (mRS) score
of 0–2] 3 months after stroke. Secondary outcomes at 3 months were the mRS, time to achieve walking
50 m, serious adverse events, quality of life (QoL) and costs at 12 months. Tertiary outcomes included a
dose–response analysis.
Data sources: Patients, outcome assessors and investigators involved in the trial were blinded to
treatment allocation.
Results: We recruited 2104 (UK, n = 610; Australasia, n = 1494) patients: 1054 allocated to VEM and
1050 to UC. Intervention protocol targets were achieved. Compared with UC, VEM patients mobilised
4.8 hours [95% confidence interval (CI) 4.1 to 5.7 hours; p < 0.0001] earlier, with an additional three
(95% CI 3.0 to 3.5; p < 0.0001) mobilisation sessions per day. Fewer patients in the VEM group (n = 480,
46%) had a favourable outcome than in the UC group (n = 525, 50%) (adjusted odds ratio 0.73, 95% CI
0.59 to 0.90; p = 0.004). Results were consistent between Australasian and UK settings. There were no
statistically significant differences in secondary outcomes at 3 months and QoL at 12 months. Dose–response
analysis found a consistent pattern of an improved odds of efficacy and safety outcomes in association
with increased daily frequency of out-of-bed sessions but a reduced odds with an increased amount of
mobilisation (minutes per day).
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Limitations: UC clinicians started mobilisation earlier each year altering the context of the trial. Other
potential confounding factors included staff patient interaction.
Conclusions: Patients in the VEM group were mobilised earlier and with a higher dose of therapy than
those in the UC group, which was already early. This VEM protocol was associated with reduced odds of
favourable outcome at 3 months cautioning against very early high-dose mobilisation. At 12 months,
health-related QoL was similar regardless of group. Shorter, more frequent mobilisation early after stroke
may be associated with a more favourable outcome.
Future work: These results informed a new trial proposal [A Very Early Rehabilitation Trial – DOSE
(AVERT–DOSE)] aiming to determine the optimal frequency and dose of EM.
Trial registration: The trial is registered with the Australian New Zealand Clinical Trials Registry number
ACTRN12606000185561, Current Controlled Trials ISRCTN98129255 and ISRCTN98129255.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 54.
See the NIHR Journals Library website for further project information. Funding was also received from the
National Health and Medical Research Council Australia, Singapore Health, Chest Heart and Stroke
Scotland, Northern Ireland Chest Heart and Stroke, and the Stroke Association. In addition, National
Health and Medical Research Council fellowship funding was provided to Julie Bernhardt (1058635), who
also received fellowship funding from the Australia Research Council (0991086) and the National Heart
Foundation (G04M1571). The Florey Institute of Neuroscience and Mental Health, which hosted the trial,
acknowledges the support received from the Victorian Government via the Operational Infrastructure
Support Scheme.
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Glossary
AVERT intervention protocol A protocol for use by clinical staff to guide the delivery of the very early
mobilisation and usual care interventions.
AVERT Online A password-protected, trial-specific web-based management system.
Contamination When the witnessing of a different intervention makes others change their usual care
practice (consciously or unconsciously).
Counting mobilisations If a patient performs a mobilisation (e.g. walks to toilet with help or is sat out of
bed) and then rests for 5 minutes, then their next mobilising activity (e.g. walking back from the toilet or
getting back into bed) constitutes another mobilisation.
Dose A session of mobilisation given to AVERT patients.
Early mobilisation Starting out of bed, sitting, standing and walking early after stroke with no defined
time from stroke onset.
Excessive fatigue When the patient reports a score of > 13 on the Borg Perceived Exertion Scale and/or
AVERT staff assess that the patient is excessively fatigued (e.g. the patient’s functional performance
worsens significantly during the intervention).
Mobilisation The patient is assisted and encouraged in functional tasks, including activities such as sitting
over the edge of the bed, standing up, sitting out of bed and walking. Upper limb movement was
intended to be integrated into functional activities as appropriate. Mobilisations were performed by the
AVERT nurse and/or the AVERT physiotherapist. Support staff, such as therapy assistants and students,
could also be trained to provide mobilisations.
Nurse’s record of mobilisation sessions The time each session started and the type of each session was
recorded on AVERT Online or, if the website was not available, data were temporarily recorded on the
paper nurses recording form until such time it could be entered online.
Physiotherapist’s record of mobilisation session The date and time each session started, the minutes
and content of each session were recorded via AVERT Online. If the online forms were unavailable, paper
therapist recording forms could be used to temporarily collect the information until such time it could be
entered online.
Time to first mobilisation The time from stroke onset to the time of the patient’s first mobilisation out
of bed (assisted or independent). This did not include the initial assessment by the AVERT physiotherapist.
Transient ischaemic attack Stroke-like symptoms that resolve completely within 24 hours.
Very early The earliest possible time after a consented patient had suffered a stroke to their first
mobilisation intervention (≤ 24 hours).
Very early mobilisation The earliest possible time after a consented patient had a stroke to their first
out-of-bed mobilisation.
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aHR adjusted hazard ratio
aOR adjusted odds ratio
AQoL assessment of quality of life
AVERT A Very Early Rehabilitation Trial
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EM early mobilisation
HR hazard ratio
HRQoL health-related quality of life
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Plain English summary
Despite the many recent improvements in stroke care, it is not clear which components are the mostimportant. Early active rehabilitation (mobilisation) represents a simple treatment that could be
provided for the majority of people with a stroke.
This clinical trial included people admitted to hospital with a stroke in 56 hospitals in five countries
(UK, Australia, New Zealand, Malaysia and Singapore). Those who agreed to participate were assigned at
random to either usual care (UC) in the stroke unit or very early mobilisation (VEM) (assisted to get out of
bed within 24 hours of the first sign of stroke). This continued frequently for the first 14 days or until
discharge from the stroke unit. All participants were followed up wherever they were living 3 months and
12 months later. A trained health-care worker gathered information about their ability to move about,
their ability to carry out everyday activities, their mood, their quality of life and any costs associated with
their care.
A total of 2104 participants took part in the trial. At 3 months, fewer participants in the VEM group were
independent in everyday activities (n = 480, 46%) than in the UC group (n = 525, 50%). There were no
significant differences in any of the other trial measures. Further analysis indicated that a good recovery
might be best achieved with short bursts of mobilisation activity repeated regularly.
Using the information from this study, we are planning a new trial to better understand how early stroke
rehabilitation can be delivered to maximise every patient’s recovery.
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Scientific summary
Background
The last two decades has seen a substantial change in the way that stroke patients are managed. We
now have several interventions available that have good evidence of benefit for acute stroke patients.
Arguably the most important of these is stroke unit care, which comprises a complex package of specialist
multidisciplinary stroke care involving nurses, therapists and doctors. However, this is a complex intervention
and it is difficult to provide firm advice on the key components of stroke unit care. Many descriptive studies
have reported that early mobilisation (EM) (starting out of bed, sitting, standing and walking early after
stroke) is believed to be an important contributor to the benefit of stroke units. However, EM is poorly
described and defined. This trial focuses on very early mobilisation (VEM) commencing within 24 hours of
stroke onset as a key component of stroke unit care.
Very early mobilisation comprises the commencement of sitting, standing and walking training out of bed
after stroke within 24 hours of stroke onset, using a clinical protocol that tailors the activity to the severity
of stroke. The biological rationale for VEM is based on the following.
1. There is good evidence that bed rest is often harmful.
2. Some of the most common and serious complications after stroke are those related to immobility.
3. Modern concepts of brain recovery after injury suggest a window of opportunity for exploiting brain
plasticity and encouraging repair.
However, there are also concerns about the potential harm of VEM and, in particular, due to reduced
cerebral blood flow caused by adopting an upright position too early. In view of these uncertainties,
Professor Julie Bernhardt of the University of Melbourne began the A Very Early Rehabilitation Trial
(AVERT) programme of work. This comprised Phase I observational studies, followed by a Phase II safety
and feasibility randomised controlled trial (RCT) and, finally, the main multicentre international RCT (AVERT
Phase III) that is reported here.
Objectives
The primary aim of this trial was to investigate the effectiveness of a protocol to implement VEM after
stroke; with commencement of frequent out-of-bed activity within 24 hours of stroke onset, compared
with usual care (UC).
The objectives of AVERT were to address four main questions.
1. Does VEM reduce death and disability at 3 months post stroke?
2. Does VEM reduce the number and severity of complications at 3 months post stroke?
3. Does VEM improve quality of life (QoL) at 12 months post stroke?
4. Is VEM cost-effective?
Methods
The AVERT was a pragmatic, prospective, parallel-group, multicentre, international, RCT with blinded
assessment of outcomes and an intention to treat analysis. The National Institute for Health Research
(NIHR) Health Technology Assessment (HTA) programme grant supported the UK component of the trial.
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Setting
Acute stroke units in 56 hospitals in five countries: UK (England, Scotland, Northern Ireland and Wales),
Australia, New Zealand, Malaysia and Singapore.
Participants
Acute stroke patients (confirmed first or recurrent stroke, cerebral infarct or intracerebral haemorrhage)
who were admitted to a stroke unit within 24 hours of symptom onset. Treatment with recombinant tissue
plasminogen activator (rtPA) was allowed with the agreement of the responsible clinician. Exclusion criteria
included significant premorbid disability, competing care needs or acute medical instability.
Procedures
Informed consent was obtained from the patient or their nominated representative. Patients were invited
to take part in a trial that was testing ‘different types of rehabilitation’. Baseline data were entered on the
AVERT Online electronic data capture system prior to randomisation.
Randomisation
After entry of baseline data, the online system allocated the patient to a treatment group using a 1 : 1
ratio, with computer-generated block randomisation stratified for site and severity. Patients were allocated
to receive either UC alone or VEM in addition to UC. The VEM intervention commenced as soon as
patients were recruited and lasted for 14 days, or until the patient was discharged from the stroke unit
(whichever was sooner). Following randomisation, baseline patient data were collected on baseline
demography, mobility scale for acute stroke, star cancellation test and time to first mobilisation (TTFM).
Interventions
The AVERT intervention protocol was followed for all patients randomised. Regardless of intervention
group, the AVERT nurses and physiotherapists recorded information about all mobilisations via the online
trial system.
Usual care was provided at the discretion of the individual sites. Trial staff documented usual stroke unit
care at their site. At each site, UC was monitored to ensure that UC did not change, or changes
were clarified.
The VEM intervention comprised the following key features.
l It was to begin within 24 hours of stroke onset.
l It was to focus on out-of-bed sitting, standing and walking activities.
l VEM was delivered in at least three out-of-bed sessions in addition to UC.
l Nursing and physiotherapy mobilisations were titrated according to patient functional level.
Patients allocated to VEM were managed by physiotherapy and nursing staff trained in the study procedures
(AVERT nurses and physiotherapists), who followed a prescribed approach based on the baseline assessment
of patient abilities from level one (fully dependent) to level four (little or no dependence). Usual risk
assessments and lifting policies were applied to all mobilisations. Prior to, and during, the first mobilisation,
an assessment of physiological variables was required and mobilisation was stopped if physiological variables
changed beyond specified limits. VEM activities were repeated and varied as appropriate and could be
reduced if associated with excessive fatigue. Nurses and therapists frequently worked together, but on
Saturdays the AVERT nurse was responsible for providing and recording mobilisations.
The UC group received usual post-stroke care and the number and type of mobilisations were not
prescribed but were recorded. AVERT Online was used to record therapy and nursing input to both VEM
and UC groups and any deviations to the protocol were documented and reported. Care was taken not to
record VEM interventions in the routine clinical records.
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Blinding
Several steps were taken to maintain the integrity of the trial.
l Patients and families were not told of their allocation group.
l Treatment allocation was not written in the medical records.
l AVERT staff ensured that other staff were not aware of treatment allocation.
l The blinded outcome assessor was remote from the ward and did not have contact with any
clinical care.
Outcomes
The primary outcome was survival without major disability [modified Rankin scale (mRS) score of 0–2] at
3 months after stroke. Secondary efficacy outcomes were an assumption-free ordinal shift across the range
of the mRS, time (days) to walk 50 m unassisted and the proportion of patients achieving unassisted
walking by 3 months. Secondary safety outcomes at 3 months were fatal and non-fatal serious adverse
events (SAEs). SAEs of interest were neurological (stroke progression and recurrent stroke) and immobility
related (pulmonary embolism, venous thrombosis, urinary tract infection, pressure sores and pneumonia).
All fatal and non-fatal SAEs were reported according to standard definitions and independently
adjudicated. At 12 months, an assessment of health-related quality of life (HRQoL) was made, using the
assessment of quality of life, with costs assessed using a resources questionnaire.
Subgroup analyses were prespecified for age, stroke severity, stroke subtype (infarct or haemorrhage),
treatment with rtPA and TTFM, as well as an exploratory analysis of association between treatment dose
and patient outcome.
Sample size
We estimated that a sample of 2104 patients would be required to provide an 80% power to detect a
significant intervention effect (p = 0.05) with adjustments for 5% drop-in and 10% drop-out. The trial
was powered to detect an absolute risk reduction of a poor outcome (mRS score of 3–6) of at least 7.1%.
The statistical and cost analysis plans were prespecified and published in advance. The primary outcome
analysis used a binary logistic regression model with treatment group as an independent variable and mRS
at 3 months as the dependent variable, with intention-to-treat analysis. Baseline stroke severity and age
were included as treatment covariates.
A series of subgroup and exploratory analysis were prespecified to explore the range of any treatment
effect and to allow analysis of association between treatment dose and patient outcome.
Results
A total of 25,237 patients were admitted within 24 hours of stroke onset, of whom 23,133 were
ineligible. Main reasons for ineligibility were a lack of available recruiting staff on duty, medical instability
or premorbid disability. A total of 2104 patients were recruited between July 2006 and October 2014;
1054 received VEM and 1050 received UC. A total of 34 patients were found to have a non-stroke
diagnosis and 26 were never mobilised. These patients remained within the intention-to-treat analysis.
Baseline characteristics were well matched between groups. The median time to randomisation was
18 hours after stroke, 80% were experiencing a first stroke and 45% were classified as having
moderate–severe stroke (National Institutes of Health Stroke Scale score of > 7). A total of 26% were aged
> 80 years and 24% received rtPA.
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Patients allocated to VEM began mobilisation within 24 hours of stroke and maintained earlier and higher
levels of out-of-bed activity than UC patients. However, it was noted that the median TTFM in the UC
group reduced during the study period. Overall, 965 (92%) VEM patients were mobilised within 24 hours
compared with 623 (59%) in the UC group. There were no substantial regional differences in the delivery
of the intervention.
Primary outcome
A total of 2083 (99%) patients were included in the 3-month follow-up.
At 3 months, fewer patients in the VEM group had a favourable outcome (mRS score of 0–2) than in the
UC group. A total of 480 (46%) VEM patients had a favourable outcome compared with 525 (50%)
in the UC group. This resulted in the significant difference between groups on the prespecified analysis
[adjusted odds ratio (aOR) 0.73, 95% confidence interval (CI) 0.59 to 0.90; p = 0.004]. Sensitivity analysis
produced similar results and unadjusted analysis of the primary outcome showed a similar (but borderline
significant) direction of effect (p = 0.068). Subgroup analysis of the primary outcome showed a consistent
pattern favouring UC across all the main subgroups. There was a suggestion of poorer outcomes with
VEM in patients with severe stroke and intracerebral haemorrhage but these did not achieve statistical
significance (test for interaction p > 0.05).
Secondary outcomes
Assumption-free ordinal analysis across the whole mRS did not show a significant difference between
groups (aOR 0.94, 95% CI 0.85 to 1.03; p = 0.193). Similarly, there were no significant differences in
walking ability (aOR 1.04, 95% CI 0.94 to 1.15; p = 0.459), case fatality at 3 months (aOR 1.34, 95% CI
0.93 to 1.93; p = 0.113) or non-fatal SAEs (incidence rate ratio 0.88, 95% CI 0.72 to 1.07; p = 0.194).
For HRQoL, the median assessment of QoL (interquartile range) for the VEM group was 0.47 (0.07–0.81)
and for the UC group was 0.49 (0.08–0.81) (p = 0.865).
Tertiary outcomes
Further prespecified analyses explored the relationship between treatment received and patient outcomes.
These indicated that a favourable outcome (mRS score of 0–2), survival and recovery of walking at 3 months
were positively associated with an increased frequency of mobilisation sessions. In contrast, a more prolonged
duration of out-of-bed mobilisation activity was associated with a poorer outcome. This pattern was observed
in logistic regression analysis and confirmed with a classification and regression tree analysis.
Meta-analysis of early mobilisation trials
We identified a total of nine RCTs, including AVERT, that had tested EM (within 48 hours) after stroke
compared with UC. Across all trials, the median delay to starting mobilisation was 18.5 hours in the EM
group and 33.3 hours in the UC group. EM showed non-significant increase in the odds of death or
dependency (odds ratio 1.10, 95% CI 0.94 to 1.29).
Conclusions
This is the largest randomised trial of its kind and required strong interdisciplinary collaboration. Most
patients underwent first mobilisation within 24 hours of stroke but the earlier, more frequent, higher-dose
mobilisation was associated with a poorer outcome than UC. As usual stroke unit care varied from site to
site and is complex in nature. It is oversimplistic to simply advise UC.
The AVERT results raise several important research questions; in particular, what are the physiological and
molecular changes induced that may be harmful in some patients, who should we target for EM and how
do we best describe the key characteristics of EM. These questions are being taken forward in a more
detailed meta-analysis. We also propose to undertake a further dose–response trial (AVERT–DOSE) to
explore the effect of frequency and dose of rehabilitation on efficacy and safety outcomes.
SCIENTIFIC SUMMARY
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Trial registration
This trial is registered with the Australian New Zealand Clinical Trials Registry number
ACTRN12606000185561, and Current Controlled Trials ISRCTN98129255 and ISRCTN98129255.
Funding
Funding for this study was provided by the HTA programme of the NIHR. Funding was also received
from National Health and Medical Research Council Australia, Singapore Health, Chest Heart and Stroke
Scotland, Northern Ireland Chest Heart and Stroke, and the Stroke Association. In addition, National
Health and Medical Research Council fellowship funding was provided to Julie Bernhardt (1058635), who
also received fellowship funding from the Australia Research Council (0991086) and the National Heart
Foundation (G04M1571). The Florey Institute of Neuroscience and Mental Health, which hosted the trial,
acknowledges the support received from the Victorian Government via the Operational Infrastructure
Support Scheme.
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Chapter 1 Introduction
Modern stroke unit care
The management of stroke patients has progressed greatly in the last two decades1,2 and several
interventions have provided good evidence of benefit for acute stroke patients.1–8 These include:
1. stroke unit care3 (a complex package of specialist multidisciplinary stroke care involving nurses,
therapists and doctors)
2. aspirin for ischaemic stroke4
3. intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) for ischaemic stroke5
4. mechanical thrombectomy for major ischaemic stroke6
5. emergency decompressive surgery for malignant middle cerebral artery syndrome.7
Among these interventions, the stroke unit effect has potentially the greatest population impact as it
combines both moderate effectiveness and broad applicability.1,2 However, as it is a complex intervention it
is difficult to be certain about the key components of stroke unit care.8 Descriptive studies have reported
that early mobilisation (EM) (starting out of bed, sitting, standing and walking early after stroke) is widely
thought to be an important contributor to the stroke unit effect.8–10 The other potentially important
components include (1) co-ordinated multidisciplinary care, (2) skilled and specialised staff, (3) training
and education of staff and (4) protocols of care covering common problems.8,9 This trial focuses on the
mobilisation component of the stroke unit rehabilitation intervention.
Rehabilitation
The term rehabilitation covers a broad philosophy and range of interventions aiming to help an individual
recovering from disabling illness to minimise the impact of that illness on their level of dependence on
external support.11 The modern classification of diseases in the International Classification of Functioning,
Disability and Health framework considers rehabilitation to comprise an interaction between the impact
of the disease, the characteristics of the individual and the nature of their environment.11 Rehabilitation
professionals aim to act on different levels of the illness to minimise the impact on the individual.11
In the context of acute stroke, early rehabilitation usually covers the key impairments experienced by
patients in the acute stage of the illness.11 These include swallowing impairment, language and speech
impairment, motor impairment, reduced mobility, reduced balance and reduced ability to carry out
self-care activities. An early focus on mobilisation is one that is likely to be relevant to a substantial majority
of acute stroke patients.
Early mobilisation
Early mobilisation comprises the commencement of sitting, standing and walking training out of bed
early after stroke. Early descriptions of stroke units frequently refer to EM and it is thought to make an
important contribution to the effectiveness of stroke unit care.9,10 However, there are disagreements about
the role of EM.10
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Arguments around mobilisation
The biological rationale for EM is based on three principal lines of argument: (1) there is good evidence
that bed rest has a harmful impact on cardiovascular, respiratory, muscular, skeletal and immune systems
across many conditions11,12 and is likely to slow recovery; (2) some of the most common and serious
complications after stroke are those related to immobility13–16 (we know that the routine day of most
acute stroke patients is largely inactive;17,18 therefore, introducing frequent training out of bed may reduce
the risk of complications of immobility); and (3) current concepts of biological recovery after brain injury
suggest a narrow window of opportunity for brain plasticity and repair.19 If the brain indeed remodels
itself based on experience20 then early task-specific training may well have an important contribution to
improving recovery.21,22
However, we must acknowledge that there are also concerns about potential harm of EM,10,23 particularly
in the first 24 hours after stroke onset. These concerns include haemodynamic considerations, such as fears
that raising the patient’s head early after stroke will impair cerebral blood flow and cerebral perfusion23 or,
in the case of intracerebral haemorrhage, increase the risk of inducing further bleeding.24 As a result of
these theoretical concerns, some clinicians have advocated initial bed rest for stroke patients.23
Given these uncertainties about the practice of EM in acute stroke patients we sought to carry out A Very
Early Rehabilitation Trial (AVERT) in acute stroke patients that focused on very early (commencing within
24 hours of stroke onset), frequent out-of-bed mobilisations in the first 14 days.
AVERT programme
The AVERT programme of work that was run by Professor Julie Bernhardt of the University of Melbourne
and began with Phase I observational studies. These studies demonstrated that most acute stroke patients
were inactive for most of the time17,18 but that this pattern of inactivity varied between hospitals.17 She also
demonstrated that there was considerable variation of opinion and clinical uncertainty among health-care
professionals about the value of very early mobilisation (VEM).23 These studies led to the AVERT Phase II
safety and feasibility randomised controlled trial (RCT)25,26 and the closely related Very Early Rehabilitation
or Intensive Telemetry After Stroke (VERITAS) trial27 carried out in Glasgow by Professor Peter Langhorne.
These trials indicated that VEM was feasible and in the case of AVERT Phase II could be carried out within
24 hours of stroke onset. This approach was observed to be safe,25–27 showed signals for improvements in
recovery25–28 as well as indicating that EM was probably cost-effective.29
Justification for the current study
The preparatory work carried out in AVERT Phases I and II led to the planning and conduct of the definitive
AVERT Phase III trial.30 This was planned as a pragmatic, international, multicentre Phase III RCT with the
power to evaluate the efficacy and safety of VEM after stroke. This report outlines the AVERT Phase III
international trial with some specific emphasis on the UK contribution. Much of this work has already been
published by the AVERT group.30–36 We will also refer to two related studies that were nested within the
AVERT programme. These studies contribute to the understanding of AVERT, but were not specifically
included in the original Health Technology Assessment (HTA) programme trial application. These comprise
(1) a qualitative process evaluation37 and (2) a study of the generalisability of the AVERT results.38
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Chapter 2 Methods
Aims and objectives
The primary aim of this trial was to investigate the effectiveness of a protocol to implement VEM after
stroke; an earlier start with frequent out-of-bed activity compared with usual care (UC), which is
traditionally started later (> 24 hours).
The objectives of AVERT were designed addressed four main questions:
1. Does VEM reduce death and disability at 3 months post stroke?
2. Does VEM reduce the number and severity of complications at 3 months post stroke?
3. Does VEM improve quality of life (QoL) at 12 months post stroke?
4. Is VEM cost-effective? [Note: this aspect of the trial programme was not funded by the current National
Institute for Health Research (NIHR) HTA programme grant.]
Our clinical hypotheses were as follows:
1. VEM would improve functional outcome at 3 months.
2. VEM would reduce immobility related complications.
3. VEM would accelerate walking recovery with no increase in neurological complications.
4. VEM would result in improved QoL at 12 months.
5. VEM would be cost-effective.
We aimed to carry out a large multicentre pragmatic trial recruiting a broad range of acute stroke patients
including those aged > 80 years, those with intracerebral haemorrhage, those who had received rtPA and
those admitted to stroke units in a range of different hospital types (small and large, urban and regional).
Trial design
We carried out a pragmatic, prospective, parallel-group, multicentre, international Phase III RCT with
blinded assessment of outcomes and an intention-to-treat analysis. Full details of the trial rationale and
statistical analysis plan30 were published in advance.
Study settings
The trial was carried out in the acute stroke unit of 56 hospitals in five countries: UK (England, Scotland,
Northern Ireland and Wales), Australia, New Zealand, Singapore and Malaysia. Stroke units were housed in
a range of hospital settings including local and regional hospitals (see list in Appendix 2).
Participants
We aimed to include all eligible patients aged ≥ 18 years with a confirmed first or recurrent stroke (infarct
or intracerebral haemorrhage) who were admitted to a stroke unit within 24 hours of onset. Exclusion
criteria are listed below and included significant premorbid disability, acute deterioration, admission to the
intensive care unit, competing care needs or physiological instability. Recruitment and informed consent
could take place in the emergency room or in the acute stroke unit.
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Eligibility
All patients (aged ≥ 18 years) admitted with stroke diagnosis (first or recurrent stroke, infarct or
haemorrhage) were screened for suitability for inclusion into the trial. If a patient was found to be
ineligible for inclusion into the trial, the reason was recorded on the stroke patient-screening log.
A diagnosis of transient ischaemic attack (TIA) would not have been considered eligible and the patient
would not have been recruited into the trial. However, if a patient was recruited into AVERT who,
clinically, appeared to have stroke symptoms and was considered eligible but later assessment confirmed a
TIA or other diagnosis, the patient remained in the trial and continued to be followed up until completion.
Inclusion criteria
l Informed consent obtained from the patient or a responsible third party.
l Patients aged ≥ 18 years with a clinical diagnosis of first or recurrent stroke, infarct or haemorrhage.
l Patients admitted to hospital within 24 hours of the onset of stroke.
l Patient for admission to the acute stroke unit.
l Patients who receive thrombolysis could be recruited if the attending physician permits and if
mobilisation within 24 hours of stroke was permitted.
l Consciousness: at a minimum, the patient must at least be able to react to verbal commands.
l Patients could participate in AVERT if they were already recruited to non-intervention trials
(e.g. imaging) if dual recruitment was permitted by the ethics committee.
Exclusion criteria
l Too disabled before stroke [prestroke modified Rankin scale (mRS) score of 3, 4 or 5].
l Patient diagnosed with TIA.
l Deterioration in patient’s condition in the first hour of admission resulting in direct admission to
intensive care unit, a documented clinical decision for palliative treatment (e.g. those with devastating
stroke) or immediate surgery.
l Concurrent diagnosis of rapidly deteriorating disease (e.g. terminal cancer).
l A suspected or confirmed lower limb fracture at the time of stroke preventing the implementation of
the mobilisation protocol.
l Patients could not be concurrently recruited to drug or other intervention trials.
l Unstable coronary or other medical condition that were judged by the investigator to impose a hazard
to the patient by involvement in the trial.
l Unstable physiological variables:
¢ systolic blood pressure of < 110 mmHg or > 220 mmHg
¢ oxygen saturation of < 92% with supplementation
¢ resting heart rate of < 40 or > 110 beats per minute (b.p.m.)
¢ temperature of > 38.5°C.
Randomisation and masking
Ethics review boards approved the study at all sites. Informed consent was obtained from all patients or
their nominated representative. Eligible participants were invited to participate in a trial that was testing
‘different types of rehabilitation’ but were not given specific information about the two approaches.30
METHODS
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After informed consent was obtained, a medical history and physical examination was performed.
The following stroke assessments were carried out:
l premorbid mRS39
l baseline mRS39
l National Institutes of Health Stroke Scale (NIHSS) score40
l Oxfordshire Community Stroke Project41 classification. A paper case report form (CRF) was completed
by the AVERT team member (see Appendix 3).
Baseline NIHSS, OSCP (Oxfordshire Community Stroke Project) classification, premorbid mRS and the date of
the stroke were all entered into the AVERT Online electronic data capture system prior to randomisation.
AVERT Online randomly allocated the treatment group with the result immediately notified to the investigator.
Participants were randomised (in a 1 : 1 ratio) through a secure remote, web-based, computer-generated
block randomisation procedure with an average block size of six. Permuted blocks of various lengths were
used to ensure allocation concealment.
Randomisation was stratified by:
1. study site
2. stroke severity using the NIHSS score,40 for which mild is a NIHSS score of 1–7, moderate is a NIHSS
score of 8–16 and severe is a NIHSS score of > 16.42
Participants were allocated to receive either usual stroke unit care alone, or usual stroke unit care in
addition to the experimental intervention, VEM. VEM patients were provided the first mobilisation as soon
as they were recruited and additional mobilisations according to the protocol. The intervention period
lasted 14 days or until the patient was discharged from stroke unit care, whichever was sooner.
Patients were not aware of their treatment group and outcome assessors plus the investigators involved
in the conduct of the trial and data management were blinded to the group assignment. To try and reduce
the risk of contamination of the UC intervention, staff providing the VEM protocol were trained to conceal
the mobilisation protocol and group allocation. The patient’s participation would be terminated if consent
had been withdrawn or if the patient’s safety had been considered to be at risk.
Procedures
Following randomisation, the trial staff obtained the following patient data within 24 hours:
l demographic information
l Mobility Scale for Acute Stroke (MSAS)43
l Star cancellation test: a screening tool to detect the presence of unilateral spatial neglect30
l Time to first mobilisation (TTFM): the date, time and staff performing the first mobilisation.
The AVERT intervention protocol
The intervention protocol was not published or distributed except to trials intervention staff. AVERT staff
from within the stroke unit team (i.e. site investigators, physiotherapists, nurses) were trained by clinical
trial managers to deliver the AVERT intervention protocol at site initiation and investigator meetings,
with refresher and new staff training provided on an ongoing basis.35 This complex intervention required
staff to work together to achieve the VEM and UC mobility targets. Trial staff agreed not to distribute or
disseminate the protocol and to keep the protocol in a secure location.
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To aid protocol description, the key intervention definitions are summarised in Box 1.
The intervention protocol was followed for all randomised patients. Information about the group to which
the patient had been randomised was known only by the AVERT physiotherapist and nursing staff. The
protocol for the interventions was not intended to replace any clinical decision-making of the individual
therapists and nurses involved in the treatment delivery. However, the expectation was that they would
adhere to the protocol whenever possible.
The protocol for VEM interventions and UC was continued until day 14 of the patient’s stay in the stroke
unit or until discharge from the stroke unit (whichever was sooner). If the patient was palliated then VEM
was discontinued and follow-up with trial assessments continued until death or 12-month follow-up.
BOX 1 Definitions used
Dose: a session of mobilisation given to AVERT patients.
Very early: the earliest possible time after a consented patient had suffered a stroke to their first mobilisation
intervention (≤ 24 hours).
Mobilisation: the patient was assisted and encouraged in functional tasks, including activities such as sitting
over the edge of the bed, standing up, sitting out of bed and walking. Upper limb movement would have been
integrated into functional activities as appropriate. Mobilisations were performed by the AVERT nurse and/or
the AVERT physiotherapist. Support staff such as therapy assistants and students could also be trained to
provide mobilisations.
Counting mobilisations: when a patient performed a mobilisation (e.g. walked to the toilet with help or was
sat out of bed) and rested for ≥ 5 minutes, then their next mobilising activity (e.g. walking back from the toilet
or getting back into bed) would have constituted another mobilisation.
TTFM: this is the time from stroke onset to the time the patient is first mobilised out of bed (assisted or
independent). This does not include the initial assessment by the AVERT physiotherapist.
Physiotherapist’s record of mobilisation sessions: the date, time, minutes and content of each session were
recorded via AVERT Online. If the online forms were unavailable, paper forms could be used to temporarily
collect the information until such time as it could be entered online.
Nurse’s record of mobilisation sessions: the date and time it started and the type of each mobilisation would
have been recorded on AVERT Online or, if the website was not available, data were temporarily recorded on
the paper nurse recording form until such time as they could be entered online.
Excessive fatigue: if the patient reported a score of > 13 on the Borg Perceived Exertion Scale and/or AVERT
staff assess that the patient is excessively fatigued (e.g. the patient’s functional performance worsened
significantly during the intervention).
Contamination: when the witnessing of a different intervention makes others change their UC practice
consciously or unconsciously.
METHODS
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Very early mobilisation interventions
The components of usual stroke unit care, including normal physiotherapy and nursing procedures,
were provided at the discretion of the individual sites. In addition to UC, the VEM intervention included
four important features.
1. It had to begin within 24 hours of stroke onset.
2. The focus had to be on sitting, standing and walking activities (i.e. out of bed).
3. VEM delivered in at least three out-of-bed sessions per day in addition to UC.
4. Nursing and physiotherapy mobilisations were titrated each day, according to patient’s functional level.
The content of nursing and physiotherapy mobilisations were detailed, task-specific activities targeting the
recovery of standing and walking. It was tailored to accommodate four levels of functional ability and was
adjusted daily in line with participant recovery. The usual risk assessments and lifting policies were applied
to all mobilisations. Even following the protocol, clinician judgement was still required when the patient’s
suitability to get out of bed was assessed.
Principles of very early mobilisation
The principles of the VEM intervention were developed in consultation with the early rehabilitation team in
the acute stroke unit in Trondheim, Norway,9 and used in AVERT Phase II.25 Trained physiotherapy and
nursing staff helped patients to continue task-specific out-of-bed activity that was focused on recovery of
active sitting, standing and walking. The frequency and intensity (amount) was guided by the intervention
protocol. This was titrated according to functional activity baseline and monitored daily and adjusted with
recovery. For example, low-functioning dependent patients (level 1) had a target of active sitting with
assistance with each session lasting between 10 and 30 minutes. Higher-functioning patients (level 4) would
have a target of standing and walking with each session lasting 10 minutes and with no restricted maximum.
The frequencies of sessions were varied according to the patient’s functional level. Passive sitting was not
classified as a mobilisation activity and sitting for > 50 minutes at a time was discouraged. The intervention
continued for 14 days or until discharge. Physiotherapists and nurses had separate intervention targets but
worked together to deliver the intervention dose. Mobilisation activities were all recorded online.
The key principles were as follows.
1. The target dose (the number of interventions, the type of intervention and the amount of time spent
with each VEM patient) was additional to usual stroke unit nursing and therapy and was titrated
according to the patient’s level of functional ability.
2. Patients were recruited as soon as possible after stroke onset, until 24 hours (day 0). The first VEM
commenced as soon as possible after recruitment and could be provided when the patient arrived on
the ward, or earlier if they were in the emergency department. The VEM target TTFM was within
24 hours from stroke. When patients were routinely mobilised within 24 hours at any site, the target
VEM time was 5 hours less than UC.
3. Patients should not rest in bed for long periods of the day unless they were medically unstable.
4. If medically stable (not specifically restricted to bed), patients were helped to perform functional
(out of bed) activities for the prescribed VEM dose according to the patient’s functional level.
5. Patients who were stable enough to sit out of bed or sit up over the side of the bed with help
were assisted to do so for the prescribed VEM dose according to the patient’s functional level.
If, on the first 3 days, they required the moderate or maximum assistance of others to move themselves
from chair to bed, they could not be left to sit out of bed for longer than 50 minutes each time.
6. When sat out of bed, patients would have been comfortably seated in a supportive chair or wheelchair
with the hemiplegic upper limb supported.
7. The VEM safety assessment was strictly adhered to for the first mobilisation out of bed. This
involved measurement of vital signs and was critical to the safety of the mobilisation.
8. For patients randomised to the VEM group, the AVERT nurse and physiotherapist worked together to
achieve a daily target for the frequency of sessions and minutes of physiotherapy mobilisation.
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The target number of sessions and minutes of physiotherapy to be delivered each day
was dictated by the level of functional ability at the start of each day
Level of functional ability
The AVERT staff assessed the patient’s functional ability using the MSAS as soon as possible after
recruitment and then at the start of each day. The patient was assessed as one of the four functional
levels (Table 1). The daily assessment of level and the daily mobilisation targets were communicated to the
study team. The level assigned to the patient was not changed throughout the day. If the patient’s level
of performance fluctuated, clinicians adjusted VEM interventions according to patient status. Usual risk
assessments and lifting policies were applied to all mobilisations.
First very early mobilisation safety assessment
The first VEM mobilisation out of bed was strictly governed by a safety assessment. If the safety
assessment failed then the first mobilisation did not commence until the patient achieved the
safety criteria.
For the first VEM sit out-of-bed mobilisation post stroke, the following procedure was followed.
Before first mobilisation
Step 1
The following physiological variables were required:
1. systolic blood pressure of 110–220 mmHg
2. oxygen saturation of ≤ 92% supplementation (see note on page 9)
3. resting heart rate of 40–110 b.p.m.
4. temperature of < 38.5 °C.
TABLE 1 Assessment of functional level
Level Definition Patient description
1 Equivalent to sitting from supine, MSAS Low arousal (responded to voice but required physical prompting)
Score = 1–4 Fully dependent. Unable to sit on the edge of the bed without the
assistance of 1 or 2 people
2 Equivalent to sitting from supine, MSAS Followed commands (verbal or non-verbal/gestures)
Score = 5–6 Moderate to high dependence. Able to sit on the edge of the bed
but would requires assistance and/or supervision. Able to stand
with assistance
3 Equivalent to gait MSAS Follows commands
Score = 2–4 Moderate dependence. Able to walk with moderate to maximum
assistance
4 Equivalent to gait MSAS Low/no dependence
Score = 5–6 Able to walk with minimal/no assistance
Reproduced with permission from Luker et al.37 © 2016 Luker et al. Open Access This article is distributed under the terms
of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
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Note:
l Oxygen saturation was measured without supplemental oxygen.
l Oxygen was stopped for 1 minute. If SpO2 was < 92%, oxygen supplementation was resumed and
maintained throughout the mobilisation.
l Blood pressure was measured in the unaffected arm. Oxygen saturation was measured on the
affected arm.
l If blood pressure, heart rate and oxygen saturation were within acceptable limits then the patient
proceeded to the next step.
Performing the first mobilisation
Step 2
l The back of the bed was raised to > 70° of hip flexion. The measures of blood pressure, heart rate and
oxygen saturation were repeated.
l If blood pressure, heart rate and oxygen saturation were within acceptable limits then the patient
proceeded to the next step.
l If blood pressure drop was > 30 mmHg then the patient remained in bed, but was reassessed at a
later time.
Step 3
l The patient was assisted to sit over the edge of the bed (feet on the floor if able). This may have
required the assistance of one or two people and the patient may have required the assistance of one
person to maintain sitting balance.
l The measures of blood pressure, heart rate and oxygen saturation were repeated.
l If blood pressure, heart rate and oxygen saturation were within acceptable limits then the intervention
would have proceeded to the next step.
l If blood pressure drop was > 30 mmHg then the patient remained in bed and would have been
reassessed at a later time.
Step 4
l Sitting was for 5 minutes and measures of blood pressure, heart rate and oxygen saturation
were repeated.
l If blood pressure, heart rate and oxygen saturation were within acceptable limits, the intervention
proceeded to the next step.
l If blood pressure drop was > 30 mmHg then the patient remained in bed, and reassessed at a
later time.
Step 5
l An appropriate level of assistance was used (hoist or manual assistance dependent on routine
assessment findings) and the patient was transferred to a comfortable chair with adjustable back to
allow an angle of 90°–100° hip flexion.
l Measures of blood pressure, heart rate and oxygen saturation were repeated.
l If measures were within acceptable limits then the patient maintained sitting and was monitored
for comfort.
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The first out-of-bed mobilisation was interrupted and the patient returned to bed if:
l in the clinician’s judgement, the patient was not tolerating the mobilisation (i.e. became less
responsive, developed a headache, became nauseated or vomited or became pale or clammy)
l systolic blood pressure was < 100 mmHg or > 230 mmHg
l systolic blood pressure decrease was > 30 mmHg
l heart rate was > 120 b.p.m.
l oxygen saturation was < 90%.
Maximum sitting time for sitting out of bed was 50 minutes each time, for the first 3 days.
What if a very early mobilisation patient could not have achieved the
first mobilisation?
Factors that would have affected a patient’s ability to mobilise may have included (but were not limited to)
(1) vital signs not within the normal listed limits, (2) an adverse event (AE) that would have led to a
mobilisation restriction for a period of time (e.g. acute myocardial infarction, lower limb fracture, pneumonia,
carotid endarterectomy) or (3) a deterioration which led to palliation.
In the case of a temporary interruption to mobilisation due to an event similar to those listed above,
mobilisation was recommenced as soon as possible. The patient’s physiological variables were reviewed
every few hours (step 1). Clinical judgement was used and the first mobilisation was attempted when the
patient physiological variables were within limits. When a mobilisation was planned, but not able to be
performed, staff submitted a therapist or nurse recording form with the time and reason not mobilised.
Whenever possible, VEM resumed at the earliest opportunity.
Usual care group
Participants who were randomised to receive UC received the usual post-stroke unit care. Prior to trial
commencement, baseline UC was reported by trial staff at each site. Typical UC is described in Table 2.
Mobilisation activity was not prescribed but all mobilisations were recorded. UC patient mobilisations at
each site were monitored for change during the trial.
Recording of mobilisation sessions
Mobilisation data for both UC and VEM patients were recorded by the AVERT physiotherapist, ward
physiotherapist and occupational therapist and/or the AVERT nurse(s) using therapist and nurse recording
forms, respectively, on AVERT Online. For convenience, paper therapist and nurse recording forms (Figures 1
and 2) were sometimes used to initially record mobilisations and then the data were transferred to AVERT
Online. VEM interventions were not recorded in routine medical records.
The AVERT nurse(s) recorded all mobilisations that they were responsible for initiating that were conducted
alone or with an AVERT physiotherapist, ward physiotherapist, occupational therapist or other assistant.
Mobilisations in which the AVERT nurse helped either the AVERT physiotherapist or ward physiotherapist/
occupational therapist for study patients (either group) were recorded by the therapist that initiated the
mobilisation. The nurse involvement was acknowledged in the recording of the mobilisation. This
prevented double reporting of a same mobilisation.
METHODS
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TABLE 2 Usual care mobilisations
Level Patient description Nursing activities Physiotherapy activities
1 Low arousal Approximately one mobilisation
every 1 or 2 days
Approximately one treatment every
1 or 2 days
Fully dependent
2 or 3 Moderate – high
dependence
Approximately two mobilisations
per day
Approximately one treatment per day,
including a mobilisation
4 Low dependence Approximately four mobilisations
per day
Approximately may/may not have received
treatment, would have been encouraged
to have mobilised independently
Note: this aspect varied greatly Note: this aspect varied greatly
Note
Usual care may have differed from this description at some hospitals and UC would have continued to be provided
according to routine practice.
Reproduced with permission from Luker et al.37 © 2016 Luker et al. Open Access This article is distributed under the terms
of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
FIGURE 1 Example of the paper therapist recording form.
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Equipment
Existing equipment (e.g. beds, standing hoists, standing frames, tilt tables, chairs, lap trays, gait aids, arm
supports, safety belts, etc.) from each hospital were utilised as per usual ward policy and availability. Ward
lifting policies were applied to all mobilisations for AVERT patients. The vulnerable hemiplegic shoulder
was cared for with the use of lap trays when the patient was seated and the provision of slings used for
transfer and walking activities.
Adherence to protocols
The online recording system allowed the intervention staff to document all mobilisations, including attempted
mobilisations and reasons for when the patient was not mobilised according to protocol. Intervention staff
received feedback from an external monitor about their compliance with the trial protocol. These were
provided in quarterly compliance summaries and were reviewed regularly by the Data Safety and Monitoring
Committee.
Contamination was a potential problem for this trial. This was because all patients in this study were
situated on a single ward. This made it difficult to keep other staff on the ward from seeing the intervention
FIGURE 2 Example of the paper nurse recording form.
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staff work with patients who had been randomised to VEM. If contamination had occurred, the results of
the trial would have been diluted because intervention and UC would have become more alike.
Contamination was considered to have occurred if VEM was provided to UC patients or became UC for a
large number of patients. Measures to reduce the potential of the intervention practices to be adopted
by staff other than the AVERT staff included security of the intervention protocol and procedures to stop
ward staff observing VEM sessions. The Data Safety and Monitoring Committee monitored contamination
throughout the trial.
Data collection
Source data relating to each patient were maintained in the patient’s medical record.
Source data relating to the intervention therapy given to the patient were not recorded in the patient’s
medical record. The therapy information was recorded in the web-based therapy/nurse forms (see
Figures 1 and 2) on AVERT Online; data were also recorded in the individual patient’s paper CRF, which
would have been supported by information documented in the patient’s medical record or clinical notes.
Blinding
We recognise that blinding is vital for the integrity of any RCT. As the AVERT physiotherapists and nurses
were delivering the interventions, they were not blinded to the interventions but protocols were in place to
conceal allocation group to all other ward staff.
The following measures were followed to maintain blinding for the AVERT study:
l A patient or their family were never told of the group to which they had been randomly allocated,
even if they asked.
l The AVERT physiotherapists never wrote VEM interventions in the medical record and AVERT nurses
recorded only standard information and did not refer to frequency of intervention provided.
l Anyone who did not need to know the patients group were never told, even if they asked.
l The AVERT staff ensured that other staff and AVERT patients did not become aware of the details of
the VEM. VEM activities were conducted behind curtains with patients screened from other ward staff,
and mobilisations performed off the ward were provided whenever this was possible.
l The blinded assessors assigned to the trial site were not on the ward when the trial took place and did
not witness treatments that patients had received.
l The blinded assessor, who conducted assessments, was never told the group to which patients were
allocated. The assessor had been trained in what they could and could not ask participants, therapists,
nurses and other staff whom they encountered.
l The blinded assessor informed AVERT ward staff if it was necessary to visit the ward for any reason,
which minimised the risk of an intervention session being witnessed. Every effort was made by AVERT
staff to ensure that a session was not witnessed by the blinded assessor.
Participant assessments
Outcome assessments were done in person or by telephone by a trained assessor who was not working in
the study stroke unit and was blinded to treatment allocation.
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Three-month assessment
At 3 months post stroke, the assessor located the patient and conducted the assessment, which included
the following.30
l mRS:39 a commonly used scale for measuring the degree of disability or dependence in the daily
activities of people who have suffered a stroke or other causes of neurological disability.
l Irritability, anxiety and depression assessment (IDA):44,45 following stroke.
l Barthel Index:46 an ordinal scale used to measure performance in activities of daily living.
l assessment of quality of life (AQoL).47
l Rivermead Motor Assessment Scale48 (RMAS): assesses the motor performance of patients with stroke
and was developed for both clinical and research use.
l 50-metre walk:30 assessed if the patient had not achieved walking during the 14-day intervention period.
l Montreal Cognitive Assessment (MoCA):49 a cognitive screening test designed to assist health
professionals in detecting mild cognitive impairment.
l Cost of care: the cost CRF collects resource use on acute hospital length of stay, discharge location,
ambulance services, rehabilitation, stroke-related rehospitalisations, change of accommodation, aids,
home modifications, community services, return to work, informal care hours and country-specific
services (e.g. UK outpatient therapy; Asian maid services in the home).
l AEs, important medical events (IMEs) and serious adverse events (SAEs) (see below).
Adverse events
An AE is defined as any untoward medical occurrence in any participant involved in the study and that
does not have a causal relationship to the study intervention. This included any worsening of a pre-existing
event. AEs were recorded in the patient’s medical record and reporting commenced from the time of
informed consent. Events were recorded in the patient’s CRF and included the date of onset, description,
severity and duration and whether or not it was thought to be related to the study intervention.
All AEs were collected from the time of the patient’s consent until the end of the intervention period and
were followed until the event was resolved or had been stabilised.
Important medical events
The IMEs were prespecified events that are important outcomes measures for this study. These
events included:30
l falls (with no soft tissue injury, with soft tissue injury, with bone fracture)
l stroke progression (defined as a worsening stroke, in the clinician’s view, in the same vascular territory
as the initial event occurring during the first 14 days)
l recurrent stroke (defined as a new stroke event beyond 14 days (in the clinician’s view)
l pulmonary embolism
l deep-vein thrombosis
l myocardial infarction
l angina
l urinary tract infection
l pressure sores
l pneumonia
l depression (clinically diagnosed).
Serious adverse events
A SAE was an AE or IME that met any one of the following criteria:
l resulted in death
l was life-threatening
METHODS
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l required inpatient hospitalisation
l prolonged hospitalisation (if an event occurs while the patient is in hospital, which in itself prolongs the
patient stay)
l resulted in persistent or significant disability.
Up to 3-month follow-up all IMEs, serious or not serious, were reported. After 14 days, we recorded new
AEs that were classified as serious but were not IMEs. From 3–12 months, SAEs were collected.
Twelve-month assessment
At 12 months, the final assessment was conducted by the blinded assessor. The assessor made contact
with the patient/relative/carer and organised the meeting.
At this visit, all 3-month assessments were repeated, except for the MoCA.
Outcomes
Primary outcome
The primary outcome was survival without major disability (mRS score of 0–2) at 3 months after stroke.
A favourable outcome was defined as mRS score of 0 (no symptoms), 1 (impairment but no disability) or
2 (independent but with minor disability). A poor outcome was defined as mRS score of 3 (disability but
able to walk), mRS score of 4 (disabled and unable to walk), mRS score of 5 (bed-bound and in need of
full nursing care) or mRS score of 6 (death).
Secondary outcomes
Secondary outcomes included an assumption-free ordinal shift39,40 of the mRS across the full range of the
scale. This measures a change in the mRS across the whole range of the scale rather than just across one
threshold. We also obtained time taken to achieve unassisted walking for 50 m and the proportion of
patients achieving walking by 3 months. Death and the number of non-fatal SAEs were recorded up to
3 months.
Serious adverse events were recorded according to standard definitions and included IMEs relevant to acute
stroke patient recovery (see above). Serious adverse events and deaths were independently adjudicated by
an outcome committee who were blinded to treatment allocation. This included a review of the source
data if necessary. The classification of complications of interest were neurological (stroke progression and
recurrent stroke) and complications of immobility (deep-vein thrombosis, pulmonary embolism, pneumonia,
urinary tract infection and pressure sores). At 12 months, we recorded health-related quality of life (HRQoL)
and items of patient costs.
Tertiary outcomes
These are outlined in the statistical analysis plan30 and include:
l IDA45
l Barthel Index46
l RMAS48
l MoCA.49
The tertiary outcomes are not reported in detail here.
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Subgroup analyses
In view of the complex nature of the VEM intervention a number of exploratory analyses were prespecified.30
In particular, subgroup analysis by age, stroke severity, stroke subtype (infarct or haemorrhage), treatment
with thrombolysis (rtPA) and TTFM. We also prespecified an exploration of the dose of the intervention in
terms of (1) TTFM, (2) frequency of mobilisation and (3) total amount of time undergoing the intervention.
Withdrawal from treatment and data collection
We anticipated that some participants would wish to withdraw from treatment. In that circumstance, the
reason and date of withdrawal were documented and they were invited to allow further collection of
follow-up data. Clearly, if the participant refused further follow-up then all treatment and data collection
ceased at that point. We considered analyses based on last result carried forward in the event of significant
loss of information.
Data retention
All study documents were confidential. Each site was issued with an investigator site file in which to store
study documents. All of the study-related documents were stored in a locked area and accessible only to
study staff.
At the completion of the study, all site study data and materials have been archived, at site, and have been
stored in a secure area for a period of ≥ 7 years if required by hospital procedures.
Power calculation and sample size
The trial was powered to detect an absolute risk reduction of a poor outcome (mRS score of 3–6) of at
least 7.1%. This threshold was based on (1) a consensus among clinicians and researchers that an absolute
risk reduction of this size would be clinically meaningful and (2) observational data indicating that a
hospital routinely practising EM compared with a similar Australian data set had a 9.1% better outcome
on the similar variable of death or institutional care (31.8% vs. 40.9%). If EM accounted for 78% of this
benefit9 then the absolute difference would be 7.1%.
We estimated that a sample of 2104 patients would be required to provide 80% power to detect a
significant intervention effect (two-sided p = 0.05) with adjustments for 5% drop-in and 10% drop-out.
Statistical analysis was prespecified and published in advance.30 Stata® (StataCorp LP, College Station, TX,
USA)/IC (version 13) was used for all analysis. For the primary analysis we used an intention-to-treat
approach with the assumption that data were missing at random. We also explored the sensitivity of our
results to plausible departures from this assumption. This used both a selection model (to model the
mechanism of missing data) and a pattern mixture model (modelling the differences between observed
and missing data).
Statistical methods
We used standard methods for handling of missing data.30,50 The primary efficacy analysis was carried out
on an intention to treat basis with an assumption that data were missing at random.30 We explored the
sensitivity of our conclusions to plausible departures from this assumption and used both a selection model
and pattern mixture model of the differences between observed and missing data. The results were
plotted out over a range of assumptions.
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We did the primary efficacy analysis used the binary logistic regression model, with treatment group as an
independent variable and mRS outcome at 3 months as the dependent variable. This was dichotomised
into scores of 0–2 as favourable outcome and scores of 3–6 as poor outcome. Baseline stroke severity
(NIHSS) and age were included as treatment covariates for adjustment purposes.
The primary outcome analysis included subgroup analysis based on age (< 65 years, 65–80 years and
> 80 years), stroke severity (mild NIHSS 1–7, moderate 8–16 and severe > 16), stroke type (ischaemic vs.
haemorrhagic), treatment with tissue plasminogen activator, TTFM (< 12 hours, 12–24 hours and
> 24 hours) and geographical region (Australia/New Zealand vs. UK, Australia/New Zealand vs. Asia),
with adjustment for stroke severity and age.
We also estimated the treatment effect on the mRS using an ordinal analysis at 3 months with the
assumption-free Wilcoxon Mann–Whitney U-test generalised odds ratio (OR) approach.51,52 This provided a
measure of effect size with confidence interval (CIs), which was stratified by age and stroke severity. Time
(days) taken to achieve unassisted walking of 50 m was analysed using the Cox regression model with
treatment group as the independent variable, the time to unassisted walking (censored at 3 months) as the
dependent variable, and age and baseline NIHSS as covariates. The estimated effect size is presented as a
hazard ratio (HR) with corresponding 95% CI. The analysis of walking status (yes or no) was analysed with
a binary logistic model using treatment group as the independent variable and walking status as the
dependent variable.
We used a binary logistic regression model to analyse mortality outcomes. Treatment group was the
independent variable and death at 3 months was the dependent variable. Age and stroke severity were
treatment covariates. We used negative binomial regression to compare the expected counts of serious
complications between groups at 3 months. We report the estimated effect sizes and corresponding
95% CI as incidence rate ratios (IRRs) adjusted for age and stroke severity.
We wished to determine whether or not practice had shifted during the course of this trial. We did this by
testing the association between treatment effect and trial duration by including an appropriate interaction
term into the logistic regression model used in the primary analysis. We also did an exploratory analysis in
which we examined the effect of time since the start of the trial on differences in dose characteristics
between the two groups. We used regression models with an interaction term for treatment by time since
the start of the trial; a median regression model was used for TTFM and median session frequency and a
binomial regression model was used for median daily minutes per session and total treatment time over
the intervention period (total minutes).
End-point analyses
Primary end point: the primary outcome was planned as a ‘between-group’ comparison of mRS at
3 months, analysed across the whole distribution of scores subject to the validity of shift analysis model
assumptions. If the assumptions for shift analysis were not met, 3-month mRS was to be dichotomised into
good outcome (mRS score of 0–2) and poor outcome (mRS score of 3–6), and the groups were compared
using a binary logistic model. Although the trial was under way, new ordinal approaches to analysis
were developed, tested and gained acceptance in acute stroke trial (see the statistical analysis plan).
The management committee determined that an assumption-free ordinal approach to analysis should be
included as a secondary outcome (statistical analysis plan). Therefore, the analysis plan was changed such
that the 3-month mRS results were dichotomised into good outcome (mRS score of 0–2) and poor outcome
(mRS score of 3–6), and the groups compared using a binary logistic model.30 The primary analysis was
adjusted with baseline NIHSS and premorbid mRS as covariates. Unadjusted results were also to be shown.
The intervention effect was represented in terms of ORs. Other potential prognostic variables such as age,
stroke type and side of stroke were included in subgroup efficacy analyses.
DOI: 10.3310/hta21540 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 54
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Langhorne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
Secondary patient end points: regression models for count data were used to compare SAEs between groups at
3 months. Risk ratios, adjusted as per primary analysis, including age and NIHSS as covariates, were reported.
The odds of achieving unassisted walking at 3 months was analysed using binary logistic regression
analyses [adjusted odds ratios (aORs) and 95% CIs]. Cox regression analysis was used to analyse the time
(days) to achieve unassisted walking. This was presented as adjusted hazard ratios (aHR) with 95% CIs and
was censored at 3 months.
Mortality outcomes at 3 months were analysed using binary logistic regression with death as the
dependent variable (aOR with 95% CI). The dose effect on counts of SAE was analysed using binomial
regression (adjusted incident rate ratio with 95% CI). Different subtypes of SAE (immobility related,
neurological) were analysed separately.
Health-related QoL analysis was planned as a multivariable median regression model with a treatment
group as independent variable and the AQoL score as the dependent variable. To estimate the effect of
intervention group on AQoL scores at 12 months, treatment covariates for adjustment purposes would
include baseline NIHSS, age and sex.
Data sharing and archiving
All deidentified trial data have been archived in secure facilities for a minimum period of 7 years.
The options of data sharing arrangements were not available at the trial commencement and were not
included in participant consent processes.
Economic evaluation at 12 months
The economic evaluation was not included in the NIHR HTA programme funding. However, the wider AVERT
programme did include a health economic analysis;34 therefore, we summarised the resource use data
collected for an economic evaluation. We prospectively collected resource use data within the trial using
standard data collection tools. The primary economic evaluation planned is a cost-effectiveness analysis
comparing resource use during the 12 months of follow-up. The health outcomes of the VEM intervention
were measured against a UC comparator. It was also intended to have included a cost–utility analysis.
For the cost-effectiveness analysis, the primary outcome is a mRS score of 0–2 at 12 months. It was
intended that the cost–utility analysis used HRQoL expressed as quality-adjusted life-years gained over a
12-month period. This was measured using the mRS and the assessment of QoL.
Data collection tools to capture resource use were piloted in the AVERT pilot study29 and then further
adapted to accommodate local service provision in different countries. An exploratory analysis of the
resource use data was planned to consider the relationship between patterns of service use in health
outcomes within the trial. These health outcomes included QoL. A further objective explored economic
impacts of stroke on patients, families, the broader community and the health sector.
The methods for assessing safety, effectiveness and QoL have already been published in the statistical
analysis plan.30 The economic analysis plan complements the statistical analysis plan and was finalised prior
to the 12-month data collection period being completed.34
The economic analysis plan describes key study variables for the economic evaluation, outlines the primary
cost-effectiveness analysis and describes proposed exploratory analysis. The development of the economic
analysis plan was guided using recommended standards.53 The economic analyses are under way; however, a
UK-specific economic evaluation will not be undertaken as not supported with NIHR HTA programme funding.
METHODS
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Exploratory analyses
To further investigate the interaction between dose characteristics and patients and a favourable outcome
we used (1) binary regression analysis and (2) a classification and regression tree (CART) analysis (Salford
predictive modeller software suite version 7, Salford Systems, San Diego, CA, USA).
The CART is a binary partitioning statistical method that starts with the total sample. It then uses a
stepwise approach to split the sample in to subsamples that are homogeneous in a defined outcome.54
The input variable that achieves the most effective split is dichotomised by automated analysis at an
optimal threshold, maximising the homogeneity within, and separation between, resulting subgroups. A
10-fold internal cross-validation is used to maximise model performance that is assessed as the area under
the receiver operating characteristic (ROC) curve. The internal cross-validation divides the data randomly
into 10 groups with nine used to build the model (training data set) and one used to validate the model
(testing data set). CART also numerically ranks each input to build the tree by relative importance. In our
analysis, we included all prespecified subgroup variables (patient age, NIHSS, stroke type, treatment with
rtPA), group allocation and the three dose characteristics (TTFM, frequency and daily amount). This analysis
explored the relative importance of each variable in association with achieving a favourable outcome
(mRS score of 0–2). A further analysis (CART II) investigated multidimensional relationships between dose
characteristics alone and favourable outcome.55
Both approaches to exploratory analysis examined the three main characteristics of treatment dose:
1. TTFM out of bed (hours)
2. frequency – median number of out-of-bed sessions per patient per day
3. daily amount – median minutes of out-of-bed activity per patient per day.
We also recorded total amount (total minutes of out-of-bed activity over the whole intervention period) to
account for varying lengths of stay in hospital.
Nurses recorded the type of activity and the time of the day each activity began. This did not include total
time in minutes as this was not routine practice. Physiotherapists recorded the type of activity, the time that
the activity began and the total out-of-bed activity (minutes), as this was incorporated in normal practice.
Therefore, physiotherapy data alone contributed to the variables of daily amount (minutes) and total amount
(minutes) of out-of-bed activity. Both nursing and physiotherapy data contributed to TTFM and frequency of
mobilisations. For the definition of frequency of mobilisation, episodes of sitting, standing or walking activity
had to be separated from another episode of activity by more than 5 minutes of rest (e.g. in a chair).
In an attempt to avoid excessive collinearity between daily amount and total amount we tested two
different models that were adjusted for age and baseline stroke severity for all the analysis:
1. Model 1 – TTFM, frequency (median daily number of out-of-bed sessions) and amount (median daily
out-of-bed session time in 5-minute increments),
2. Model 2 – TTFM, frequency (median daily number of out-of-bed sessions) and amount (total minutes
out-of-bed activity over the whole intervention period in 5-minute increments).
The primary exploratory analysis was carried out using binary logistic regression models with favourable
outcome (mRS score of 0–2) at 3 months as the dependent variable.
Meta-analysis of comparable trials
We wished to set the AVERT results in the context of other similar RCTs. We updated the searches of the
existing systematic review,56 searching MEDLINE, EMBASE, CINAHL (Cumulative Index to Nursing and Allied
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Health Literature), Cochrane Stroke Group trials register, several international ongoing trials registers,
reference lists of articles and also performed citation searching up to 2015. Foreign language translations
were sought. Two review authors assessed trial eligibility, quality and performed data extraction. We included
any trial that compared EM after stroke (within 48 hours) with a more delayed mobilisation. The primary
outcome was death or poor outcome (dependency or institutionalisation) at follow-up with the use of a mRS
score of 3–5 as the preferred definition of poor outcome. We used a fixed-effects model to estimate ORs and
95% CIs, with the use of a random-effects model in the event of substantial heterogeneity (I2 > 50%).
Patient and public involvement
Stroke survivors in Australia contributed to the original trial development. In particular, Ms Brooke Parsons
(a stroke survivor) was involved in the development of the proposal and the monitoring and progress of
the trial through her role on the Trial Steering Committee. Each individual study site had varying degrees
of patient and public involvement.
Role of the funding source
The various funders of the AVERT international trial had no role in study design, data collection, analysis
and interpretation or in the writing of the report. The author team had full access to all data in the study.
METHODS
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Chapter 3 Qualitative process evaluation
Introduction
As stated in the introduction, we also refer to two related studies that were not specifically included in
the original HTA programme trial application but were nested within the AVERT programme and
contribute to its understanding. These are a qualitative process evaluation,37 which is summarised here,
and a study of the generalisability of AVERT,38 which appears in the results (see Chapter 4).
It is particularly challenging to implement multidisciplinary stroke rehabilitation interventions when the
intervention is both complex and multifaceted. This part of the trial programme aimed to better understand
how the implementation of the VEM intervention was experienced by the staff involved. It has been
reported that efforts to implement evidence-based recommendations in acute stroke units have had mixed
success. In particular, changing clinician behaviour is particularly challenging when incorporated within
pragmatic trials.57 The qualitative process evaluation summarised here aimed to help us better understand
the implementation of the VEM intervention protocol from the perspective of the health-care professionals
who were responsible for its delivery. We believed that understanding the knowledge and perspectives of
these staff would be important to both develop effective guidance in the future and implement the VEM
intervention if it was found to be effective.
The main component of this chapter was published in Luker et al.37 This article is distributed under the
terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you
give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated. The text in this chapter includes minor additions and formatting changes to the
original text.
Methods
We used the standard qualitative methodological methodologies58,59 involving AVERT trial collaborators in
Scotland, Australia and New Zealand. Ethics approvals were obtained for all three countries. The Scottish
component of recruitment was carried out as part of a Stroke Association-funded Doctor of Philosophy
(PhD) by Ms Louise Craig, who was also our first AVERT manager in the UK. The raw Scottish data relevant
to the main AVERT trial were reanalysed by colleagues in Australia using the same approach for all
included study sites.
Study sample
We used purposive sampling at participating AVERT sites. This was overseen by the trial manager in
Australia and New Zealand and by Louise Craig in Scotland. Of the 72 staff who expressed interest,
six did not eventually consent to take part and one moved abroad. We obtained informed consent from
33 physiotherapists, 18 nurses, one physiotherapy assistant and one speech pathologist. These staff
members are based in four stroke units in Scotland, 14 in Australia and one in New Zealand.
The qualitative data were collected and analysed before the primary outcome of the trial was available.
We conducted semistructured interviews facilitated by interview guides that permitted additional questions
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or probes if interesting information arose.37 The main focus of the interview was on the implementation of
the VEM protocol. The Scottish interviews were conducted between 2010 and 2011 and the Australian
and New Zealand interviews took place in 2014. They could be by telephone or face to face. Telephone
interviews commonly ran for 30 minutes, while face-to-face interviews averaged 59 minutes. Interviews
were audio-recorded, transcribed, cross-checked with participants and deidentified prior to analysis.
Analysis
We used a thematic analysis to explore the experience and perspectives of staff involved in the trial. This
approach is said to be especially relevant to multimethods health research58,59 and uses low-inference
interpretation. We inductively coded the data and set about identifying themes. Each stage incorporated
independent consideration by two or more researchers with subsequent discussion and consensus forming.
We coded the transcripts to small sections of meaning and then through an iterative process we grouped
the codes into logical and meaningful clusters in a hierarchical tree structure. This resulted in categories,
descriptive themes and subthemes (Table 3). Emergent themes, each with subthemes, were grouped into
three categories: staff experience of implementing the trial intervention, barriers to implementation of
the trial intervention and strategies to overcome barriers to intervention (see Table 3). Stroke unit staff
described the challenges of taking part in the trial and how their unit set about implementing the VEM
protocol. The recent publication37 describes the findings in detail but for the purposes of this report we
have summarised the main themes as follows.
1. Staff experience of implementing the trial intervention.
i. Extra work but rewarding: the extra work was felt to be justified by the hope that the trial might
benefit stroke patient outcomes.
ii. Team practice changes: several staff reported a positive impact on teamwork at their site.
In particular, closer working of nurses and physiotherapists and some changes in their professional roles.
– Changes to usual practice: over the duration of the trial some staff perceived a change in UC.
This was not a universal perception but was noted by a substantial minority.
2. Barriers to intervention implementation.
The main reported barriers related to the general implementation of a trial and also those specific to
the VEM intervention, in particular, the frequency of the intervention.
i. Team challenges: implementation difficulties were notable at sites that appeared to lack established
interdisciplinary team working practices.
ii. Staffing challenges: a common theme was that inadequate staffing levels made it difficult to
consistently implement the VEM protocol particularly in the face of competing demands. It was
recognised that experienced and trained staff were essential for successful implementation of
the protocol.
iii. Organisational or workplace barriers.
– The acute model and culture: there was a common view that the rapid pace and focus on early
discharge of acute hospitals rendered rehabilitation a low priority.
– Barriers to acute stroke unit access: a particular problem was that significant delays were
experienced while patients waited for a bed in the acute stroke unit.
– Competing priorities: competing organisational priorities such as discharge pressure,
accreditation work and transfer policies were commonly reported as being a challenge.
QUALITATIVE PROCESS EVALUATION
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TABLE 3 Final coding tree used in qualitative study
Themes Interviewsa Subthemes
Category 1: Staff experience of implementing the trial intervention
1 Extra work but rewarding 27
2 Team practice changes 24
Changes to UC
Category 2: Barriers to intervention implementation
3 Team challenges 19
4 Staffing challenges 37
5 Organisational or workplace barriers 28
The acute model and culture
Barriers to Acute Stroke Unit access
Competing priorities
Physical environment barriers
6 Staff attitudes and beliefs 32
Not ‘on board’
Beliefs about roles and capabilities
Beliefs about consequences
7 Patients’ barriers 35
Acuity, instability and complexity
Severity of stroke
Fatigue
Family anxiety
Category 3: Overcoming implementation barriers
8 Teamwork central to success 43
Communication and coordination
9 Getting staff ‘on board’ 35
Staff education and training
Leadership for change
10 Working differently 29
‘This is what we do here’
Shifting control
Staffing model changes
Dealing with fatigue
a Number of interviews containing data supporting the theme.
Reproduced with permission from Luker et al.37 © 2016 Luker et al. Open Access This article is distributed under the terms
of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
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iv. Physical environmental barriers: environmental barriers such as lack of equipment and chairs were
reported to be barriers.
v. Staff attitudes and beliefs.
– Resistance to change of practice: resistance to changing practice was identified at some sites
particularly among staff who were not experienced in clinical trials.
– Beliefs about roles and capabilities: mobilisation delays at some sites were due to nurses
awaiting physiotherapists to begin mobilisation.
– Beliefs about consequences: many staff assumed a positive treatment effect from VEM, which
appeared to influence their perceptions of the treatment and anecdotal outcomes.
vi. Patient barriers.
– Acuity, instability and complexity: acute health problems including unstable medical conditions
and complex problems were viewed as a common barrier.
– Severity of stroke: early delivery of the VEM protocol was viewed as challenging in patients
with drowsiness or reduced cognition. They would require more staff to assist mobilisation.
The challenges with milder strokes were mainly due to the high frequency mandated by the
VEM protocol.
– Fatigue: staff reported that fatigue was a common problem reported by patients sometimes
preventing mobilisation.
– Family anxiety: on some occasions families raised concerns that the VEM intervention was
preventing necessary rest.
3. Overcoming implementation barriers.
Many interviewees described strategies for implementing the VEM intervention in the face of the
observed barriers. These are summarised below.
i. Teamwork is central to success: units that felt they had been successful in providing the VEM
protocol frequently reported shared interdisciplinary roles with nurses, physiotherapists and others
working closely together through flexible work practices and mutual trust.
– Communication and co-ordination: a component of good interdisciplinary working was effective
communication and co-ordination between different members of staff.
ii. Getting staff on board: an almost universal theme was the importance of spending time and effort
to get staff engaged with the new VEM practice.
– Staff education and training: this was felt to be a cornerstone of getting staff involved.
– Leadership for change: implementing the VEM protocol was seen as a whole team responsibility
but required leadership.
iii. Working differently: a positive attitude to implementing the VEM protocol was seen in sites
determined to work around organisational barriers and foster a culture appropriate to the trial.
This included a willingness to relinquish some control of traditional roles and practices.
– Staffing model changes: some units reported using different staffing models involving nursing or
allied health assistants.
– Managing patient fatigue: some units reported innovative approaches to timetabling therapy to
accommodate patient fatigue.
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Discussion
The interview with staff identified some common themes.37 First, implementing the VEM protocol within
AVERT was acknowledged as being a challenging task. However, despite the challenges encountered
there was substantial enthusiasm about participation in the trial. This enthusiasm was largely driven by
an interest in the research question and the potential benefit to future stroke patients. A strong feature
of these interviews was the importance of highly effective interdisciplinary teamwork. This was widely
acknowledged as being an important factor in implementation of the VEM protocol. A second key feature
was the importance of effective leadership to champion and encourage the trial within their units.
A strength of the qualitative study was that information was collected and analysed prior to the main
AVERT trial results becoming available. Participants were generally optimistic that the trial would be
positive and this seemed to be a factor in sustaining interest over a number of years. Another study
strength was that experiences were collected across three countries, and, although there were some minor
intercountry differences,37 the similarities were more striking than the differences.
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Chapter 4 Statistical trial results
The main component of this chapter was published by the AVERT Trial Collaboration Group,31(an Open Access article) distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The text in this chapter includes minor
additions and formatting changes to the original text.
Screening and exploring threats to generalisability in the AVERT
In parallel with the main trial of AVERT, we also carried out a study to explore potential threats to
generalisability of the main results of AVERT.38 We wished to consider the impact of person, place, setting
and practice as a framework for considering generalisability. Therefore, we used a proximal similarity
model (Figure 3) to carry out this analysis of the first 20,000 patients screened for inclusion in AVERT,
which involved 44 hospitals in five countries. Of the first 20,000 patients screened for inclusion, 1158 were
recruited and randomised in AVERT.
We compared recruited patients with the target population and also explored the factors (demographic,
clinical process and site factors) that were associated with participant recruitment using a proximal
similarity model (see Figure 3) that incorporated inclusion and exclusion criteria (Figure 4).
Place
Setting and
practice
Person
AVERT
sample
Factors associated with
trial or hospital processes
(e.g. whether or not a
patient is transferred to
ICU)
Demographic and
clinical factors
(e.g. stroke type)
Factors
associated with
trial site and
country
Le
ss
 s
im
ila
r
Less similarLess
 simil
ar
Target population
FIGURE 3 Proximal similarity framework applied to the AVERT trial: a model for conceptualising the dimensions
along which the sample of patients may be similar to the target population. Each dimension (person, place, setting
and practice) is affected by specific factors that may threaten external validity. ICU, intensive care unit. Reproduced
with permission from Bernhardt et al.38 This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt,
build upon this work non-commercially, and license their derivative works on different terms, provided the original
work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
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The characteristics of participants included in the trial were broadly similar in terms of demographic
and stroke characteristics with the exception that recruited participants had a greater proportion of
men (Table 4). Late arrival to hospital (after 24 hours) was the most commonly reported reason for
non-recruitment. Overall, older and female participants were less likely to be recruited to the trial. The
reasons for exclusion of women rather than men applied to a range of reasons including refusal. Among
severe stroke patients, the odds of exclusion because of early deterioration was particularly common
(OR 10.4, 95% CI 9.3 to 11.7, p < 0.001).
RecruitedInclusion criteria
Exclusion criteria
Trial process factors
Non-recruited
Randomised
After 24 hours
mRS score of ? 3
ICU admit
Deteriorated
Coronary condition
Failed physiological
Other trial
Other
Missed
Refused
? 18 years
Clinical diagnosis of first or recurrent stroke, haemorrhage or infarct
(but not transient ischaemic attack)
As a minimum level of consciousness, patient must at least respond
to verbal commands
Attending physician of a patient who has received alteplase permits
participation
Informed consent is obtained
Recruited within 24 hours of onset of stroke symptoms
Significant pre-morbid disability: pre-stroke (retrospective)
mRS score of 3, 4 or 5
Deterioration in patient’s condition in the first hour of admission
resulting in direct admission to ICU of immediate surgery
Palliation: a documented clinical decision for palliative treatment
(e.g. those with devastating stroke) or concurrent diagnosis of
rapidly deteriorating disease (e.g. terminal cancer)
Unstable coronary or other medical condition that is judged by the
inverstigator to impose a hazard to the patient by involvement in
the trial 
Physiological state falls outside set safety limits:
•  systolic blood pressure of < 110 or > 220 mmHg
•  oxygen saturation of < 92% with oxygen supplementation
•  resting heart rate of < 40 or > 110 b.p.m.
•  temperature of > 38.5°C
Concurrent recruitment to a pharmaceutical or other intervention
trial. Patients may participate in AVERT if they are also recruited
to non-intervention trials
A suspected or confirmed lower limb fracture at the time of stroke
preventing the implementation of the mobilisation protocol
Did not meet all inclusion criteria (i.e. < 18 years, did not respond
to verbal commands or attending physician of a patient who received
alteplase did not permit participation) or recruiter identified a unique
reason for patient being unsuitable for the triala
Patient not identified by recruiting staff within 24 hours recruitment
time frame (e.g. patients who are admitted over the weekend)
Patient refuses participation
FIGURE 4 Relationship between trial inclusion/exclusion criteria and screening log categories in AVERT. a, other
reasons included (but are not limited to) patients not admitted to a stroke unit, lower limb fractures and no
treating therapist available. ICU, intensive care unit. Reproduced with permission from Bernhardt et al.38 This is an
Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0)
license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their
derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
See: http://creativecommons.org/licenses/by-nc/4.0/.
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We found that using a screening log that captured a broad range of reasons for non-recruitment added to
the collection of demographic data.38 Similarly, the use of a model to explicitly explore generalisability was
informative. However, a large screening log can only collect a limited amount of demographic and clinical
information and it is quite possible that other factors may have influenced our recruitment. The proximal
similarity model which explores person, place, practice and setting did provide some important information
about the generalisability of this trial. Overall, the external validity appeared reasonably good.
Screening and recruitment
A summary of trial recruitment in the UK and other recruiting regions, during the period of the NIHR HTA
programme grant (2012–16), is shown in Table 5. Recruitment from UK sites stood at 319 participants
at the start of 2013 (average UK recruitment rate of seven participants per month). This compared with
19 participants per month in all other sites in Australia, New Zealand and Asia. The expansion that was
possible through the NIHR HTA programme grant allowed us to recruit 291 UK participants in 2013–14
(average recruitment per month of 14 participants compared with 16 participants per month in all
other sites).
The trial profile is provided in Figure 5. A total of 25,237 patients were admitted within 24 hours of stroke
onset, of whom 23,133 were ineligible. The most common reasons were no recruiting staff available at
the time of admission, medical instability, or premorbid disability. A smaller number were enrolled in other
clinical trials or refused trial entry. Between 18 July 2006 and 16 October 2014, we randomly allocated
2104 patients to receive either VEM (n = 1054) or UC (n = 1050).
TABLE 4 Baseline demographics of recruited vs. non-recruited patients, including significance testing for differences
Features AVERT, non-recruited AVERT, recruited
Difference (p-value) –
recruited : non-recruited
n (%) 18,842 (94) 1158 (6)
Age (years), median (IQR) 75 (64–82) 73 (63–80) < 0.001
Range 15–102 18–100
Female age (years), median (IQR) 78 (61–80) 76 (66–82)
Male age (years), median (IQR) 71 (68–85) 71 (61–79)
Female, % (95% CI) 47 (47 to 48) 37 (34 to 40) < 0.001
NIHSS, n (%) < 0.001
Mild (1–7) 10,012 (53) 619 (53)
Moderate (8–16) 4934 (26) 358 (31)
Severe (> 16) 3896 (21) 181 (16)
Stroke type, n (%) 0.504
Ischaemic 16,328 (87) 1012 (87)
ICH 2514 (13) 146 (13)
ICH, intracerebral haemorrhage; IQR, interquartile range.
Reproduced with permission from Bernhardt et al. (2015).38 This is an Open Access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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TABLE 5 Regional AVERT recruitment between 2011 and 2014
Country/centre
January to
December 2011
January to
December 2012
January to
December 2013
January to
October 2014
Final
total
Northern Ireland total 20 12 2 2 59
Antrim 8 7 1 2 18
Belfast City 5 – – – 15
Craigavon 0 – – – 0
Daisy Hill 1 – – – 1
Ulster 6 5 1 – 25
Wales total 5 1 5 12
Neville Hall 5 1 5 12
Scotland total 13 26 25 30 171
Aberdeen 5 9 8 11 33
Crosshouse – – – – 3
Edinburgh – 2 4 – 6
Forth Valley 2 12 13 20 65
Monklands 3 1 26
Western – – – – 10
Wishaw 3 2 – – 28
England total 26 107 116 111 368
Blackpool – – – 17 17
Calderdale – 2 5 7
Harrogate – 4 4 7 15
Hexham 2 3 – – 5
Imperial College 9 7 8 5 29
London St George – – 2 5 7
North Devon 1 4 1 6
North Tyneside 1 8 7 1 17
QEQMH – 4 9 8 21
Royal Bournemouth – 5 18 9 32
Royal Devon 2 7 7 8 24
Royal Victoria 5 6 13 11 35
South Tyneside 2 2 3 1 8
St Mary’s IoW – 10 1 2 13
Wansbeck 3 8 4 3 18
Yeovil 1 23 24 13 61
York – 15 11 28 54
UK total (number/month) 64 (5.3) 146 (12.2) 149 (12.4) 142 (15.8) 610
Australia/New Zealand/Asia
total (number/month)
237 (19.8) 164 (13.7) 179 (14.9) 149 (15.3) 1494
Total (number/month) 301 (25.1) 309 (25.3) 322 (26.8) 271 (30.1) 2104
Note
UK had 319 participants by January 2013.
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Eligibility violations
A total of 34 patients were found to have a non-stroke diagnosis (n = 13 in VEM, and n = 21 in UC).
A total of 26 were never mobilised (n = 12 in VEM, and n = 14 in UC) (see Figure 5). These patients
remained in the trial and, if they agreed, were followed through until completion.
Participant baseline characteristics
Table 6 outlines the participant baseline characteristics that were similar between study groups. The
median time to randomisation was 18 hours after stroke and was the same in both groups. The majority
of patients (80%) were experiencing their first stroke and a large minority (45%) were classified as having
moderate or severe stroke (NIHSS of > 7). Approximately one-quarter of patients were aged > 80 years
(26%) and 24% received rtPA.
Admitted within 24 hours
of stroke onset
(n = 25,237)
Ineligiblea
(n = 23,133)
Enrolled
(n = 2104)
Randomised
(n = 2104)
Allocated to VEM
(n = 1054)
Never mobilised (n = 12)
Not stroke (n = 13)
Never mobilised (n = 14)
Not stroke (n = 21)
Allocated to UC
(n = 1050)
Assessed at 3 months (n = 1038) Assessed at 3 months (n = 1045)
Included in (n = 1054)
• Intention to treat
• Primary analysis
Included in (n = 1050)
• Had premorbid mRS score of  > 2, n = 5588
• Were enrolled in another clinical trial,
   n = 1136
• Were medically unstable or unwell,
   n = 7080
• Had no recruiter or were admitted on
   a weekend, n = 7414
• For other reasons, n = 8151
• Refused, n = 446
• Alive, n = 950
• Dead, n = 88
• Unknown, n = 6
• Refused follow-up, n = 10
• Alive, n = 973
• Dead, n = 72
• Refused follow-up, n = 5
• Intention to treat
• Primary analysis
FIGURE 5 AVERT profile. a, More than one reason possible per patient. Reproduced with permission from the
AVERT Trial Collaboration Group (2015).31 This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.3310/hta21540 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 54
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Langhorne et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
TABLE 6 Baseline patient characteristics
Features VEM (n= 1054) UC (n= 1050)
Recruitment region, n (%)
Australia and New Zealand 617 (59) 626 (60)
Asia 126 (12) 125 (12)
UK 311 (29) 299 (28)
Age (years), mean (IQR) 72.3 (62.3–80.3) 72.7 (63.4–80.4)
< 65, n (%) 331 (31%) 298 (28%)
65–80, n (%) 448 (43%) 481 (46%)
> 80, n (%) 275 (26%) 271 (26%)
Sex, n (%)
Female 411 (39) 407 (39)
Male 643 (61) 643 (61)
Risk factors, n (%)
Hypertension 707 (67) 717 (68)
Ischaemic heart disease 235 (22) 251 (24)
Hypercholesterolaemia 421 (40) 423 (40)
Diabetes mellitus 239 (23) 228 (21)
Smoking, n (%)
Never smoked 454 (43) 491 (47)
Smokera 227 (22) 204 (19)
Ex-smokera 352 (33) 341 (33)
Unknown 21 (2) 14 (1)
Atrial fibrillation 229 (22) 237 (23)
Premorbid history, n (%)
Premorbid mRS
0 799 (76) 786 (75)
1 145 (14) 158 (15)
2 110 (10) 106 (10)
Living arrangement at time of admission, n (%)
Home alone 257 (25) 275 (26)
Home with someone 781 (74) 761 (73)
Supported accommodation 16 (1) 14 (1)
Independent walking, n (%)
Without aid 908 (86) 925 (88)
With aid 146 (14) 125 (12)
Time to randomisation (hours), mean (IQR) 18.2 (12.1–21.8) 18.2 (12.5–21.8)
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Participant withdrawals
A total of 2083 (99%) of patients were included in the 3-month follow-up assessment (see Figure 5).
The main reasons for withdrawal were refusal (15 participants) and unknown (six participants). At the
12-month follow-up, 2052 (97%) completed an assessment, which showed that 24 patients were missing
and 28 refused follow-up.
For UK participants (n = 610), 3-month follow-up assessments were complete for ≥ 98% of participants
(nine withdrew). The 12-month follow-up assessments were complete for > 96% of UK participants
(15 withdrew, 10 could not be contacted).
Treatment compliance
Table 7 summarises the three crucial elements of the VEM protocol. Patients allocated to VEM began
mobilisation within 24 hours of stroke.
Patients in the VEM group successfully commenced mobilisation early after randomisation (median
18.5 hours after stroke). In the UC group, the median time to mobilisation was almost 5 hours later, but
still within 24 hours of stroke onset. The categorisation of TTFM in the VEM and UC groups is outlined in
TABLE 6 Baseline patient characteristics (continued )
Features VEM (n= 1054) UC (n= 1050)
Stroke history, n (%)
First stroke 878 (83) 843 (80)
NIHSS score, mean (IQR) 7 (4–12) 7 (4–12)
Mild (1–7) 592 (56) 578 (55)
Moderate (8–16) 315 (30) 328 (31)
Severe (> 16) 147 (14) 144 (14)
Stroke type (Oxfordshire Stroke Classification), n (%)
Total anterior circulation infarct 224 (21) 232 (22)
Partial anterior circulation infarct 340 (32) 328 (31)
Posterior circulation infarct 93 (9) 106 (10)
Lacunar infarct 255 (24) 268 (26)
Intracerebral haemorrhage 142 (14) 116 (11)
rtPA treatment, n (%)
Yes 247 (23) 260 (25)
Baseline walking (MSAS walking score), n (%)
Independent 439 (42) 416 (40)
Supervised or assisted 522 (49) 538 (51)
Unable to walk 91 (9) 96 (9)
Unknown 2 (< 1) 0 (0)
a We defined a smoker as a current smoker or a participant who had quit smoking in the past 2 years, and an ex-smoker
as a participant who had quit smoking > 2 years ago.
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Table 7. It is notable that 965 (92%) VEM patients had mobilised within 24 hours compared with 623
(59%) patients in the UC group. It was noted that the median TTFM in the UC group actually reduced
during the study period. The rate of reduction was 28 minutes per year (95% CI 11.3 to 44.6 minutes;
p = 0.001). There was no significant change in the VEM group over the same time period. As a result,
there was a significant interaction between time since commencing the trial and TTFM (p = 0.017). In
contrast, during the study period there was no significant change in the daily frequency or daily amount of
out-of-bed intervention or in the total intervention time.
Content of physical therapy and nursing
Further exploration of the intervention differences between the VEM and UC groups are shown in Figure 6.
TTFM was substantially reduced in the VEM group in all subgroups of patients except those recruited in Asia.
The frequency of out-of-bed activity was increased in all VEM subgroups, especially younger patients with
milder strokes. A similar pattern was seen in the amount of out-of-bed activity regardless of whether it was
measured per day or over the whole intervention period.
Regional differences
Figure 6 also shows the successful delivery of VEM compared with UC regimes in the UK sites. In general,
the differences were slightly less marked in the UK than other regions but, overall, UK sites delivered a
2.6-hour reduction in TTFM, with three more out-of-bed activity sessions per day. This equated to
15 minutes more out-of-bed activity per day or 90 minutes during the intervention period.
TABLE 7 Summary of interventions
Features VEM (n= 1054) UC (n= 1050) p-value
Median shift
(95% CI)
TTFM (hours) 18.5
(12.8–22.3; n= 1042a)
22.4
(16.5–29.3; n = 1036a)
< 0.0001 4.8 (4.1 to 5.7)
Frequency per personb 6.5 (4.0–9.5) 3 (2.0–4.5) < 0.0001 3 (3 to 3.5)
Daily amount per person (minutes)c 31 (16.5–50.5) 10 (0–18) < 0.0001 21.0 (20 to 22.5)
Total amount per person (minutes)d 201.5 (108–340) 70 (32–130) < 0.0001 117 (107 to 128)
IQR, interquartile range.
a Twelve patients were missing from the VEM group and 14 patients were missing from the UC group. Missing patients
were never mobilised, either because of an early SAE event, decision to palliate, or early death or transfer from the
stroke unit. For these patients, therapy and nurse recording forms were completed throughout their stroke unit stay,
with zero time and zero sessions.
b Daily sessions of out-of-bed activity.
c Minutes per day spent in out-of-bed activity.
d Total amount is over the length of stay or until 14 days after stroke (whichever took place first).
Data are median (IQR) or median (IQR; n), unless otherwise indicated.
Dose data for VEM includes components of both UC and VEM. Frequency is derived from nursing and therapist data.
Amount (minutes) is derived from physiotherapist data only. Median estimates include days when time or number of
out-of-bed sessions were zero (i.e. the patient was recorded as not getting up on that day or for that session).
Reproduced with permission from the AVERT Trial Collaboration Group (2015).31 This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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UK
Australia and New Zealand
Asia
Recruitment region
Yes
No
rtPA treated
Haemorrhage
Infarct
Stroke type
Severe
Moderate
Mild
Stroke severity
> 80
65 – 80
< 65
Age (years)
Subgroup
  604
1224
  250
  496
1582
  256
1822
  272
  638
1168
  540
  917
  621
Number of patients
– 2.58 (– 4.02 to – 1.14)
– 4.58 (– 5.50 to – 3.66)
– 1.00 (– 2.72 to 0.72)
– 3.58 (– 4.85 to – 2.31)
– 3.83 (– 4.83 to – 2.83)
– 4.50 (– 7.02 to – 1.98)
– 3.80 (– 4.67 to – 2.93)
– 9.08 (– 11.50 to – 6.66)
– 5.83 (– 7.17 to – 4.49)
– 2.16 (– 3.01 to – 1.31)
– 4.00 (– 5.78 to – 2.22)
– 4.00 (– 5.00 to – 3.00)
– 3.25 (– 4.60 to – 1.90)
Effect (95% CI)
0 4– 4
(a)
FIGURE 6 Intervention characteristics by group (VEM vs. UC) for each subgroup. (a) TTFM (hours); (b) frequency,
median daily sessions of out-of-bed activity; (c) daily amount, median minutes per day in out-of-bed activity; and
(d) total amount, minutes, over the intervention period. The forest plot shows the effect size and 95% CI for
earlier TTFM, more frequent out-of-bed sessions, higher daily amount of out-of-bed activity and higher total dose
over the intervention period in the VEM group. Titration of dose to the stroke severity is evident. Stroke severity
(NIHSS): mild = 1–7, moderate= 8–16, and severe > 16. Reproduced with permission from the AVERT Trial
Collaboration Group (2015).31 This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. (continued )
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UK
Australia and New Zealand
Asia
Recruitment region
> 24
12 – 24
< 12
TTFM (hours)
Yes
No
rtPA treated
Haemorrhage
Infarct
Stroke type
Severe
Moderate
Mild
Stroke severity
> 80
65 – 80
< 65
Age (years)
Subgroup
  610
1243
  251
  516
1212
  376
  507
1597
  258
1846
  291
  643
1170
  546
  929
  629
Number of patients
3.00 (2.04 to 3.96)
3.50 (2.54 to 4.46)
4.00 (2.50 to 5.50)
1.50 (0.18 to 2.82)
3.50 (2.53 to 4.47)
3.50 (2.46 to 4.54)
3.00 (2.04 to 3.96)
4.00 (3.06 to 4.94)
3.00 (2.01 to 3.99)
4.00 (3.06 to 4.94)
2.00 (1.10 to 2.90)
3.00 (2.04 to 3.96)
4.00 (3.05 to 4.95)
2.50 (1.54 to 3.46)
3.50 (2.53 to 4.47)
4.50 (3.55 to 5.45)
Effect (95% CI)
0 1– 1 2– 2 5– 5
(b)
FIGURE 6 Intervention characteristics by group (VEM vs. UC) for each subgroup. (a) TTFM (hours); (b) frequency,
median daily sessions of out-of-bed activity; (c) daily amount, median minutes per day in out-of-bed activity; and
(d) total amount, minutes, over the intervention period. The forest plot shows the effect size and 95% CI for
earlier TTFM, more frequent out-of-bed sessions, higher daily amount of out-of-bed activity and higher total dose
over the intervention period in the VEM group. Titration of dose to the stroke severity is evident. Stroke severity
(NIHSS): mild = 1–7, moderate= 8–16, and severe > 16. Reproduced with permission from the AVERT Trial
Collaboration Group (2015).31 This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. (continued )
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UK
Australia and New Zealand
Asia
Recruitment region
> 24
12 – 24
< 12
TTFM (hours)
Yes
No
rtPA treated
Haemorrhage
Infarct
Stroke type
Severe
Moderate
Mild
Stroke severity
> 80
65 – 80
< 65
Age (years)
Subgroup
  610
1243
  251
  516
1212
  376
  507
1597
  258
1846
  291
  643
1170
  546
  929
  629
Number of patients
15.00 (12.54 to 17.46)
23.00 (21.02 to 24.98)
28.50 (23.48 to 33.52)
11.00 (5.66 to 16.34)
23.00 (20.95 to 25.05)
19.50 (14.76 to 24.24)
20.00 (15.98 to 24.02)
21.50 (20.03 to 22.97)
20.00 (15.52 to 24.48)
22.00 (21.02 to 22.98)
12.50 (7.45 to 17.55)
22.00 (18.96 to 25.04)
25.00 (23.04 to 26.96)
14.50 (11.51 to 17.49)
20.00 (17.05 to 22.95)
28.00 (24.50 to 31.50)
Effect (95% CI)
0 4– 4 25– 25
(c)
FIGURE 6 Intervention characteristics by group (VEM vs. UC) for each subgroup. (a) TTFM (hours); (b) frequency,
median daily sessions of out-of-bed activity; (c) daily amount, median minutes per day in out-of-bed activity; and
(d) total amount, minutes, over the intervention period. The forest plot shows the effect size and 95% CI for
earlier TTFM, more frequent out-of-bed sessions, higher daily amount of out-of-bed activity and higher total dose
over the intervention period in the VEM group. Titration of dose to the stroke severity is evident. Stroke severity
(NIHSS): mild = 1–7, moderate= 8–16, and severe > 16. Reproduced with permission from the AVERT Trial
Collaboration Group (2015).31 This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. (continued )
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Participant assessments
Out of the 2104 participants randomly assigned to either VEM (n = 1054) or UC (n = 1050), 2083 (99%)
were available for 3-month mRS follow-up assessments (see Figure 5), with smaller numbers available
for other outcome measures. At the 12-month follow-up, 2052 (97%) completed a mRS assessment,
which showed that 24 patients were missing and 28 refused follow-up.
UK
Australia and New Zealand
Asia
Recruitment region
> 24
12 – 24
< 12
TTFM (hours)
Yes
No
rtPA treated
Haemorrhage
Infarct
Stroke type
Severe
Moderate
Mild
Stroke severity
> 80
65 – 80
< 65
Age (years)
Subgroup
  610
1243
  251
  516
1212
  376
  507
1597
  258
1846
  291
  643
1170
  546
  929
  629
Number of patients
90.00 (63.59 to 116.41)
142.00 (129.97 to 154.03)
175.00 (150.25 to 199.75)
87.00 (54.62 to 119.38)
146.00 (131.66 to 160.34)
132.00 (103.40 to 160.60)
124.00 (100.48 to 147.52)
137.00 (124.00 to 150.00)
141.00 (104.38 to 177.62)
134.00 (120.99 to 147.01)
84.00 (38.51 to 129.49)
142.00 (120.70 to 163.30)
129.00 (118.98 to 139.02)
102.00 (83.60 to 120.40)
144.00 (127.84 to 160.16)
146.00 (125.69 to 166.31)
Effect (95% CI)
0 125– 125
(d)
FIGURE 6 Intervention characteristics by group (VEM vs. UC) for each subgroup. (a) TTFM (hours); (b) frequency,
median daily sessions of out-of-bed activity; (c) daily amount, median minutes per day in out-of-bed activity; and
(d) total amount, minutes, over the intervention period. The forest plot shows the effect size and 95% CI for
earlier TTFM, more frequent out-of-bed sessions, higher daily amount of out-of-bed activity and higher total dose
over the intervention period in the VEM group. Titration of dose to the stroke severity is evident. Stroke severity
(NIHSS): mild = 1–7, moderate= 8–16, and severe > 16. Reproduced with permission from the AVERT Trial
Collaboration Group (2015).31 This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Primary end point: 3 months
At 3-month follow-up, fewer patients in the VEM group had a favourable outcome than the UC group
(Table 8). This resulted in a significant difference between the groups on the prespecified analysis, which
adjusted for baseline age and NIHSS (see Table 8): 480 (46%) in the VEM group had a favourable outcome
compared with 525 (50%) in the UC group (aOR 0.73, 95% CI 0.59 to 0.90; p = 0.004). Sensitivity analysis
produced similar results (Figure 7) and the treatment effect showed no interaction with time since the
commencement of the trial. Unadjusted analysis of the primary outcome showed a reduction in favourable
outcome that did not achieve statistical significance (p = 0.068).
TABLE 8 Outcomes at 3 months
Features
VEM
(n= 1038a)
UC
(n= 1045a)
Adjusted analysis Unadjusted analysis
OR, generalised OR
or HRb (95% CI) p-value
OR, generalised OR
or HRb (95% CI) p-value
Primary
Favourable
outcomec
480 (46) 525 (50) 0.73 (0.59 to 0.90) 0.004 0.85 (0.72 to 1.0) 0.068
Secondary
mRS category – – 0.94 (0.85 to 1.03) 0.193 0.94 (0.85 to 1.03) 0.202
0 90 (9) 96 (9) – – – –
1 200 (19) 204 (19) – – – –
2 190 (18) 225 (22) – – – –
3 238 (23) 218 (21) – – – –
4 140 (14) 127 (12) – – – –
5 92 (9) 103 (10) – – – –
6 88 (8) 72 (7) – – – –
Walking 50m
unassistedd
6 (5–7;
n= 1051)
7 (6–8;
n= 1049)
1.04 (0.94 to 1.15) 0.459 1.05 (0.95 to 1.16) 0.331
IQR, interquartile range.
a Sixteen patients were missing from the VEM group and five patients were missing from the UC group. These 21 patients
declined follow-up or could not be found. Missing data were analysed according to our intention-to-treat strategy
assuming missing at random. Figure 7 shows results of the sensitivity analysis.
b Point estimates are ORs for the primary outcome, generalised ORs for the secondary outcome of mRS category and HRs
for the secondary outcome of walking unassisted.
c mRS score of 0–2.
d Time at which 50% of participants walked. The number walking unassisted includes all patients who were recorded as
having walked 50m unassisted in the first 3 months. This number might include patients for whom we were unable to
obtain 3-month mRS.
Data are n (%) or median (IQR; n), unless otherwise indicated.
All analyses are adjusted for baseline NIHSS score and age.
Reproduced with permission from the AVERT Trial Collaboration Group (2015).31 This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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Secondary patient end point: 3 months
The secondary analysis included the assumption-free ordinal analysis. This did not show a significant
difference between groups across the whole mRS (Figure 8). OR (95% CI) for an improved outcome was
0.94 (0.85 to 1.03; p = 0.202) for an unadjusted analysis and 0.94 (0.85 to 1.03; p = 0.193) for an
adjusted analysis (see Table 8).
0.6
0.0 0.2 0.4 0.6
PMM exp(delta) in specified arm(s)
0.8 1.0
0.7
0.8
0.9
VEM only
Both arms
UC only
FIGURE 7 Sensitivity analysis for the primary outcome, favourable outcome (mRS score of 0–2) at 3 months.
The intention-to-treat analysis assumes that data are missing at random. The sensitivity of the results to plausible
departures from this assumption were explored. Assumptions about the missing data were expressed via a parameter
delta [exp(delta)], which measures the degree of departure from missing at random assumption (range 0–1).
The upper 95% CI is below 1 (OR 0.71, 95% CI 0.57 to 0.87; p= 0.001) for all the values of delta indicating that the
results remain significant on the sensitivity analysis. PMM, pattern mixture model. Reproduced with permission from
the AVERT Trial Collaboration Group (2015).31 This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
0
UC
VEM
20 40 60 80 100
Proportion (%)
9
9 19 18 23 14 9 8
19 22 21 12 10 7
mRS = 0
No symptoms Death
mRS = 1 mRS = 2 mRS = 3 mRS = 4 mRS = 5 mRS = 6
FIGURE 8 Patients achieving each mRS score at 3 months. Reproduced with permission from the AVERT Trial
Collaboration Group (2015).31 This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Walking ability
By 7 days after stroke, 50% of patients were able to walk unassisted and 784 (75%) were walking by
3 months in the VEM group. In the UC group, at 3 months, 796 (76%) were walking (aOR 0.83, 95% CI
0.64 to 1.07; p = 0.143). There was no significant difference in the groups in the time to walking
unassisted (Figure 9 and see Table 8).
Case fatality
At the 3-month follow-up, the overall case fatality was 8% (Table 9); 88 (8%) patients died in the VEM
group and 72 (7%) in the UC group. The main causes of SAEs are outlined in Table 9. These accounted
for two-thirds of all deaths and included stroke progression (n = 31 in the VEM group and n = 19 in the
UC group), pneumonia (n = 19 in the VEM group and n = 15 in the UC group) and recurrent stroke
(n = 11 in the VEM group and n = 7 in the UC group).
Length of hospital stay
For patients in the VEM group, the median length of hospital stay including acute care and rehabilitation
was 16 days [interquartile range (IQR) 5–44 days]. Patients in the UC group had a hospital stay of a
median of 18 days (6–43 days). The equivalent figure for acute care alone was 7 days (IQR 4–13 days) for
both patients receiving VEM or UC. The rehabilitation length of stay was 28 days (15–49 days) for the VEM
group and 30 days (16–51 days) for the UC group. The number of patients transferring from acute care to
patient rehabilitation was 492 (46%) in the VEM group and 523 (49%) in the UC group.
Adverse events
Serious adverse events: most patients did not have a SAE in the first 3 months of follow-up (see Table 9).
There was no significant difference in the proportion of patients who had non-fatal SAEs (see Table 9). We
also examined SAEs by prespecified category of complication (immobility vs. neurological). Relatively few
patients in either group had a fatal or non-fatal serious complication related to immobility (see Table 9).
The final number was 8% in each group. Serious neurological complications were recorded in < 10% of
patients in either group and there were no significant differences between the groups (see Table 9). The
most common neurological complication was stroke progression and was recorded in 72 (7%) participants
in the VEM group and 56 (5%) participants in the UC group.
Staff safety: one staff injury was reported in the VEM group.
Secondary patient end point: 12 months
A total of 2052 (97.5%) participants completed the 12-month follow-up (Figure 10). In the VEM group,
139 participants had died, 19 refused and 16 were lost, compared with 118, nine and eight participants,
respectively, in the UC group. For the UK participants (n = 610), assessments were complete for ≥ 96%
(15 withdrew, 10 could not be contacted). Therefore, 52 (2.5%) patients did not complete mRS at
12-month follow-up (see Figure 7). The aOR (adjusted for age and baseline NIHSS) for a favourable
outcome (mRS score of 0–2) in the VEM group was 0.84 (95% CI 0.68 to 1.03; p = 0.089).
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Health-related QoL: the AQoL could not be collected for 87 out of 2104 (4.1%) participants. In the VEM
group, 139 had died, 36 could not be completed (refused, incomplete, not collected by assessor) and
16 could not be contacted. In the UC group, 118 had died, 27 could not be completed and eight could
not be contacted. A death outcome was scored as zero and included in the analysis. A score of < 0 was
classified as ‘worse than death’ and 0.9–1.0 was ‘excellent’. Treatment covariates for adjustment are
baseline NIHSS, age and sex. The per cent of proxy completions (when the patients is alive but the AQoL
was completed by a family member, friend or carer) was 11.9% in the VEM group and 12.6% in the UC
group. The median AQoL IQR for the VEM group was 0.47 (95% CI 0.07 to 0.81) and in the UC group
was 0.49 (95% CI 0.08 to 0.81; p = 0.865). The adjusted median regression result was –0.0036 (95% CI
–0.045 to 0.038; p = 0.865).
TABLE 9 Deaths and non-fatal serious complications at 3 months
Features VEM (n= 1054) UC (n= 1050) OR or IRRa (95% CI) p-value
Death 88/1048 (8)b 72 (7) 1.34 (0.93 to 1.93) 0.113
Non-fatal SAEs 0.88 (0.72 to 1.07) 0.194
0 853 (81) 842 (80) – –
1 157 (15) 146 (14) – –
2 32 (3) 41 (4) – –
3 10 (1) 16 (2) – –
4 2 (< 1) 4 (< 1) – –
5 0 1 (< 1) – –
Immobility SAEsc 0.92 (0.62 to 1.35) 0.665
0 1000 (95) 997 (95) – –
1 50 (5) 46 (4) – –
2 4 (< 1) 5 (1) – –
3 0 2 (< 1) – –
4 0 0 – –
5 0 0 – –
Neurological SAEsc 1.26 (0.95 to 1.66) 0.108
0 947 (90) 967 (92) – –
1 104 (10) 78 (7) – –
2 3 (< 1) 4 (< 1) – –
3 0 1 (< 1) – –
4 0 0 – –
a Point estimates are OR for death and IRRS for all AEs.
b The 3-month outcome was missing (unknown) for six patients in the VEM group. Missing data were analysed according
to our intention-to-treat strategy assuming missing at random. The results remain stable over the range of possible
violations of this assumption.
c Immobility-related and neurological SAEs include both fatal and non-fatal complications. Immobility-related events
include pulmonary embolism, deep-vein thrombosis, urinary tract infection, pressure sores and pneumonia, and
neurological events include stroke progression and recurrent stroke.
Data are n/N (%) or n (%), unless otherwise indicated.
We did IRR analysis with event counts per person. All analyses are adjusted for age and baseline NIHSS score.
Reproduced with permission from the AVERT Trial Collaboration Group (2015).31 This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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Walking ability: at 12 months, 24% (434/1836) of alive patients were not walking 50 m. The aOR between
groups for walking at 12 months was 0.85 (95% CI 0.65 to 1.10; p= 0.222). The between-group comparison
of proportion of the number of days before patients recovered walking ability was not statistically significantly
different between groups (HR 1.02, 95% CI 0.94 to 1.13; p= 0.553).
Subgroup analyses
The prespecified subgroup analysis of the primary outcome (favourable outcome of mRS score of 0–2 at
3 months) is outlined in Figure 11. The pattern of results tended to favour the UC intervention across
all the main subgroups. The point estimate suggested that the poorest outcomes in the VEM group
were in patients with severe stroke and patients with intracerebral haemorrhage. However, within each
individual subgroup analysis, no statistically significant interactions were recorded (p > 0.05), but the trial
is underpowered to detect subgroup interactions.
Admitted < 24 hours
of stroke onset
(n = 25,237)
Enrolled
(n = 2104)
Randomised
(n = 2104)
• Alive, n = 950
• Dead, n = 88
• Unknown, n = 6
• Refused follow-up, n = 10
VEM
(n = 1054)
Assessed at 3 months
(n = 1038)
Assessed at 12 months
(n = 1019)
Included in intention-to-treat 
sensitivity analysis
(n = 1054)
UC
(n = 1050)
Assessed at 3 months
(n = 1045)
• Alive, n = 973
• Dead, n = 72
• Refused follow-up, n = 5
Assessed at 12 months
(n = 1033)
Included in intention-to-treat 
sensitivity analysis
(n = 1050)
• Alive, n = 889
• Dead, n = 139
• Unknown, n = 16
• Refused follow-up, n = 19
• Alive, n = 924
• Dead, n = 118
• Unknown, n = 8
• Refused follow-up, n = 9
FIGURE 10 Trial profile at 12-month follow-up.
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The subgroup analysis of the secondary outcome (death at 3 months) is outlined in Figure 12. The pattern
of results tended to favour the UC intervention across all the main subgroups. The point estimate
suggesting that the poorest outcomes in the VEM group were in patients with intracerebral haemorrhage
did not achieve a statistically significant level of interactions (p > 0.05, see Figure 11).
Moderator analysis
Functional outcome: further prespecified analysis explored the relationship between treatment received
and patient outcomes; this analysis included all patients in a single cohort analysis and explored
relationships within the group using binary logistic regression models and CART analysis. Baseline
characteristics of the combined participant groups are shown in Table 10. It was notable that the group
were representative of the stroke population: 25% were ≥ 80 years of age and 43% had a moderate or
severe stroke (NIHSS score of > 7) while 12% were diagnosed with intracerebral haemorrhage.
Recruitment region
Asia
Australia and New Zealand
UK
TTFM (hours)
< 12
12 – 24
> 24
rtPA treated
No
Yes
Stroke type
Infarct
Haemorrhage
Stroke severity
Mild
Moderate
Severe
Age (years)
< 65
65 – 80
> 80
244
1238
601
374
1194
515
1580
503
1828
255
1157
635
291
614
924
545
0.74 (0.40 to 1.35)
0.73 (0.55 to 0.96)
0.74 (0.51 to 1.08)
1.02 (0.62 to 1.68)
0.56 (0.42 to 0.75)
0.78 (0.42 to 1.43)
0.74 (0.58 to 0.94)
0.71 (0.46 to 1.09)
0.77 (0.62 to 0.97)
0.48 (0.25 to 0.92)
0.75 (0.57 to 0.98)
0.76 (0.53 to 1.08)
0.35 (0.11 to 1.18)
0.74 (0.49 to 1.11)
0.70 (0.52 to 0.96)
0.76 (0.50 to 1.14)
n OR (95% CI)Subgroup
0.125 0.25 0.5 1
Favours UC Favours VEM
2 4 8
FIGURE 11 Prespecified subgroup analyses: primary outcome at 3 months. None of the individual subgroup
analyses had significant treatment-by-subgroup interactions (all p> 0.05). Stroke severity (NIHSS): mild = 1–7,
moderate= 8–16 and severe > 16. Reproduced with permission from the AVERT Trial Collaboration Group (2015).31
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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The intervention characteristics for all patients are summarised in Table 11. The median TTFM was short
[20.2 hours (IQR 14.7–23.8)] and 1588 (75%) of all participants began out-of-bed activities within
24 hours of stroke onset.
In the logistic regression analysis (Table 12) a longer TTFM was associated with reduced odds of favourable
outcome (OR 0.99, 95% CI 0.98 to 1.00; p = 0.036). In the first model, the effect of timed first mobilisation
was adjusted for the median daily number of sessions (frequency) and the median daily number of minutes
(daily amount) as well as age and baseline severity (NIHSS). This should be interpreted as follows: for two
patients with a similar age and baseline stroke severity who receive a similar frequency and daily amount of
out-of-bed activity, the patient who starts mobilisation earlier has an increased odds of a favourable outcome.
We found a similar pattern of association with each of the dose characteristics for both favourable
outcome (mRS score of 0–2) and walking by 3 months (see Table 12). All three intervention variables
(timed to first mobilisation, frequency, daily amount) were significantly associated with outcome in model 1.
When keeping other variables constant, every extra 5 minutes of out-of-bed activity per day was associated
with reduced odds of favourable outcome. In contrast, increasing the frequency of sessions was associated
with an improved odds of a favourable outcome by 13% (95% CI 9% to 18%; p < 00.1) and also and
Recruitment region
Asia
Australia and New Zealand
UK
TTFM (hours)
< 12
12 – 24
> 24
rtPA treated
No
Yes
Stroke type
Infarct
Haemorrhage
Stroke severity
Mild
Moderate
Severe
Age (years)
< 65
65 – 80
> 80
247
1241
610
375
1208
515
1593
505
1841
257
1167
640
291
623
929
546
1.19 (0.27 to 5.30)
1.54 (0.97 to 2.44)
1.00 (0.52 to 1.91)
2.23 (0.64 to 7.77)
1.48 (0.85 to 2.56)
1.50 (0.71 to 3.14)
1.47 (0.95 to 2.28)
1.08 (0.56 to 2.09)
1.15 (0.77 to 1.70)
3.21 (1.13 to 9.07)
2.33 (0.95 to 5.72)
0.99 (0.53 to 1.85)
1.31 (0.78 to 2.22)
0.80 (0.26 to 2.46)
1.87 (1.05 to 3.30)
1.13 (0.67 to 1.91)
nSubgroup OR (95% CI)
0.125 0.25 0.5 1.0
Favours VEM Favours UC
2.0 4.0 8.0
FIGURE 12 Death at 3 months by group shown for each subgroup. None of the individual subgroup analyses had
significant treatment-by-subgroup interactions (all p> 0.05). Stroke severity (NIHSS): mild = 1–7, moderate = 8–16
and severe > 16. Reproduced with permission from the AVERT Trial Collaboration Group (2015).31 This is an Open
Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.
org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
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TABLE 10 Baseline characteristics of all included patients (VEM and control)
Features Patients (N= 2104)
Recruitment region, n (%)
Australia/New Zealand 1243 (59)
Asia 251 (12)
UK 610 (29)
Patient characteristics
Age (years), median (IQR) 73 (63–80)
Female, n (%) 818 (40)
Risk factors, n (%)
Hypertension 1424 (68)
Ischaemic heart disease 487 (23)
Hypercholesterolaemia 929 (40)
Diabetes mellitus 467 (22)
Atrial fibrillation 466 (22)
Smoking, n (%)
Never smoked 945 (45)
Smoker 431 (20)
Ex-smoker 693 (33)
Living arrangement at time of admission
Home alone 532 (25)
Home with someone else, n (%) 1542 (73)
Time (hours) to randomisation, median (IQR) 18 (12–22)
First stroke, n (%) 1721 (82)
NIHSS score at baseline
Median (IQR) 7 (4–12)
Mild (NIHSS 1–7), n (%) 1170 (56)
Moderate (NIHSS 8–16), n (%) 643 (31)
Severe (NIHSS score of > 16), n (%) 291 (14)
Stroke type (Oxfordshire Stroke Classification), n (%)
Total anterior circulation infarct 456 (22)
Partial anterior circulation infarct 668 (32)
Posterior circulation infarct 199 (9)
Lacunar infarct 523 (25)
Intracerebral haemorrhage 258 (12)
Treated with rtPA 507 (24)
Baseline walking (based on MSAS), n (%)
Independent 855 (41)
Supervised or assisted 1060 (50)
Adapted with permission from Bernhardt et al. (2016).33 Copyright © 2016 The Author(s). Published by Wolters Kluwer
Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of
the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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TABLE 11 Summary of mobilisation intervention for all patients
Characteristics All included patients (N= 2104)
TTFM (hours), median (IQR) 20.2 (14.7–23.8)a (n= 2078)
Frequency per personb [median daily sessions of out-of-bed activity (IQR)] 5 (3–8)
Daily amount per personc [median minutes per day spent in out-of-bed activity (IQR)] 17.5 (6–35)
Total amount per personc [minutes over the intervention periodd (median and IQR)] 120 (50–235)
a A total of 26 patients were missing data on hours to first mobilisation. These patients were never mobilised owing to an
early SAE (n= 13), decision to palliate (n = 5), early death (n= 5), transfer from the stroke unit (n= 1) or drop-out
(n = 1). For these patients, therapy and nurse recording forms were completed throughout their stroke unit stay, with
zero time and zero sessions.
b Frequency of out-of-bed activity is derived from nursing and physiotherapist data.
c Amount (minutes) of out-of-bed activity is derived from physiotherapist data only.
d Total amount of out-of-bed activity over the intervention period was estimated over the total length of stay or until
14 days post stroke (whichever occurred first).
Median estimates include days when the patient was recorded as not getting up on that day (and so n= 0).
Adapted with permission from Bernhardt et al. (2016).33 Copyright © 2016 The Author(s). Published by Wolters Kluwer
Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of
the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
TABLE 12 Association of intervention characteristics with favourable outcome (mRS score of 0–2) and
unassisted walking
Features
Favourable outcome
(mRS score of 0–2) Walking 50m unassisted
Variable OR (95% CI) p-value
Binary OR
(95% CI) p-value
Cox HR
(95% CI) p-value
Model 1
TTFM (per extra hour of time) 0.99
(0.98 to 1.0)
0.036 1.0
(0.99 to 1.0)
0.40 0.99
(0.98 to 0.99)
< 0.001
Frequency, median daily sessionsa
(per one extra session of mobilisation)
1.13
(1.09 to 1.18)
< 0.001 1.66
(1.53 to 1.80)
< 0.001 1.10
(1.09 to 1.13)
< 0.001
Daily amount, median (per extra
5 minutes of mobilisation activity)
0.94
(0.91 to 0.97)
< 0.001 0.85
(0.81 to 0.89)
< 0.001 0.96
(0.94 to 0.97)
< 0.001
Model 2
TTFM (per extra hour of time) 0.99
(0.98 to 1.0)
0.025 1.0
(0.99 to 1.0)
0.48 0.99
(0.98 to 0.99)
< 0.001
Frequency, median daily sessionsa
(per one extra session of mobilisation)
1.14
(1.10 to 1.18)
< 0.001 1.63
(1.51 to 1.76)
< 0.001 1.11
(1.10 to 1.13)
< 0.001
Total amountb (per extra 5 minutes
of mobilisation activity over
intervention period)
0.99
(0.98 to 0.99)
< 0.001 0.98
(0.98 to 0.99)
< 0.001 0.99
(0.99 to 0.99)
< 0.001
a Frequency of out-of-bed activity is derived from nursing and physiotherapist data.
b Amount (minutes) of out-of-bed activity is derived from physiotherapist data only.
All analyses are adjusted for age and baseline NIHSS score. Model 1 examines the association of an extra 5 minutes of
out-of-bed activity per day, while model 2 includes the association of an extra 5 minutes of out-of-bed activity over the
intervention period (to account for differences in length of hospital stay). The binary OR refers to walking 50m vs. not
walking 50m at the 3-month follow-up. That is, one extra session leads to fewer days required to walking 50 m, while an
extra 5 minutes daily session time is associated with more days to walking 50m.
Adapted with permission from Bernhardt et al. (2016).33 Copyright © 2016 The Author(s). Published by Wolters Kluwer
Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of
the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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improved odds of walking 50 m unassisted (66%, 95% CI 53% to 80%; p < 0.001). The pattern was
similar when the alternative model (model 2) was used.
Adverse outcomes: when exploring associations between intervention characteristics and death within
3 months, the only characteristic that reduced the odds of death was increasing session frequency
(Table 13). Non-fatal AEs showed less consistent associations with dose characteristics. It should be noted
that relatively few mobility and neurological SAEs were reported.
Classification and regression tree analysis
The CART analysis exploring the relationships with a good functional outcome (mRS score of 0–2) is
outlined in Figure 13. This includes timed first mobilisation, intervention frequency, daily amount, patient
TABLE 13 Association of intervention characteristics with death and non-fatal SAEs
Features
Deaths Non-fatal SAEs
Fatal or non-fatal
neurological SAEs
Fatal or non-fatal
immobility SAEs
Binary OR
(95% CI) p-value IRR (95% CI) p-value IRR (95% CI) p-value IRR (95%) p-value
Model 1
TTFM (per extra
hour of time)
0.99
(0.98 to 1.00)
0.07 1.0
(0.99 to 1.00)
0.71 1.0
(0.99 to 1.00)
0.45 1.00
(0.99 to 1.00)
0.59
Frequency, median
daily sessionsa (per
one extra session
of mobilisation)
0.78
(0.70 to 0.88)
< 0.01 0.99
(0.95 to 1.03)
0.55 0.89
(0.84 to 0.95)
< 0.01 0.94
(0.87 to 1.01)
0.11
Daily amount,
medianb (per extra
5 minutes of
mobilisation activity)
0.96
(0.89 to 1.04)
0.30 0.96
(0.93 to 0.99)
0.01 1.03
(0.99 to 1.08)
0.17 0.94
(0.89 to 1.00)
0.06
Model 2
TTFM (per extra
hour of time)
0.99
(0.98 to 1.00)
0.07 0.99
(0.99 to 1.00)
0.81 1.00
(0.99 to 1.00)
0.35 1.00
(0.99 to 1.00)
0.59
Frequency, median
daily sessionsa (per
one extra session
of mobilisation)
0.79
(0.71 to 0.88)
< 0.01 0.96
(0.93 to 0.99)
0.02 0.93
(0.88 to 0.98)
< 0.01 0.91
(0.85 to 0.97)
< 0.01
Total amountb (per
extra 5 minutes
over intervention
period of
mobilisation activity)
0.99
(0.98 to 1.00)
0.06 1.00
(1.00 to 1.00)
0.49 1.00
(0.99 to 1.00)
0.32 1.0
(0.99 to 1.00)
0.41
a Frequency is derived from nursing and physiotherapist data.
b Amount (minutes) is derived from physiotherapist data only.
All analyses are adjusted for age and baseline NIHSS score. Model 1 examines the association of an extra 5 minutes of
out-of-bed activity per day, while model 2 includes the association of an extra 5 minutes of out-of-bed activity over the
intervention period (to account for differences in length of hospital stay). Immobility-related SAEs included deep-vein
thrombosis, pulmonary embolism, pressure sores, pneumonia and urinary tract infection. Neurological SAEs include stroke
progression and recurrent stroke.
Adapted with permission from Bernhardt et al. (2016).33 This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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age, baseline NIHSS, stroke subtype, treatment with thrombolysis and randomisation group. We observed
good to excellent performance with a training data set (ROC 0.78) and ROC of 0.77 in a testing data set.
The relative contribution of each variable is shown on the figure. In this analysis, treatment group was not an
important discriminator of patient outcome. As expected, younger patients and those with low baseline NIHSS
scores had a higher probability of a favourable outcome. The association with intervention characteristics was
evident further down the analysis tree. For example, at terminal node 4 (see Figure 13) the greater probability
of favourable outcome was associated with more frequent short mobilisation sessions (no more than
13.5 minutes). Mobilisation frequency also split the tree for terminal nodes 5 and 6, suggesting that more
frequent sessions to achieve a higher dose was associated with an improved odds of a good outcome. In
further CART analysis (Figures 14–16), TTFM intervention frequency and amount plus group are all influential
splitters in these models.
All
[N = 2083,
n = 1004 (48%)]
NIHSS score of ≤ 7.5
[N = 2157,
n = 807 (70%)]
Aged ≤ 76.3 years
[N = 757,
n = 592 (78%)]
Aged > 76.3 years
[N = 400,
n = 215 (54%)]
Aged ≤ 86.1 years
[N = 330,
n = 191 (58%)]
Aged > 86.1 years
[N = 70,
n = 24 (34%)]
Frequency of ≤ 1.25
per day
[N = 9,
n = 0 (0%)]
Frequency of > 1.25
per day
[N = 147,
n = 73 (50%)]
Frequency of ≤ 10.25
per day
[N = 76,
n = 27 (35%)]
Frequency of > 10.25
per day
[N = 16,
n = 11 (70%)]
Amount ≤ 13.5
(minutes)
[N = 55,
n = 35 (64%)]
Amount > 13.5
(minutes)
[N = 92,
n = 38 (41%)]
NIHSS score of > 7.5
[N = 926,
n = 197 (21%)]
NIHSS score of ≤ 4.5
[N = 174,
n = 118 (68%)]
NIHSS score of > 4.5
[N = 156,
n = 73 (47%)]
FIGURE 13 Classification and Regression Tree (CART1) advanced analysis investigating associations between dose
and patient characteristics and the odds of a favourable outcome (mRS score of 0–2). Each box shows the number
(N) with the headline characteristic plus the number of them (%, highlighted in bold) with a favourable outcome
(mRS score of 0–2). Terms used include median daily number of out-of-bed sessions per day (frequency), median
daily out-of-bed activity session time (amount), age (years) and stroke severity (NIHSS). Frequency is derived from
nursing and physiotherapist data and amount (minutes) is derived from physiotherapist data only. Adapted with
permission from Bernhardt et al. (2016).33 Copyright © 2016 The Author(s). Published by Wolters Kluwer Health,
Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of
the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
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Finally, we repeated the regression analysis for the UC group alone because of the potential risk of any
unmeasured confounding by treatment group (additional unmeasured differences between treatment
groups). This repeat analysis (Table 14) indicated that the same factors were important within the UC
group alone.
Specific UK perspectives
Figure 6 also showed the delivery of VEM in different regions. This shows the successful delivery of VEM
versus UC regimes in the UK sites. In general, the differences between VEM and UC were slightly less
marked in the UK than other regions but, overall, UK sites delivered a 2.6-hour reduction in TTFM, with
three more out-of-bed activity sessions per day. This equated to 15 minutes more out-of-bed activity per
day or 90 minutes during the intervention period.
All
[N = 753,
n = 589 (78%)]
NIHSS score of ≤ 6.5
[N = 664,
n = 539 (81%)]
Aged ≤ 65.1 years
[N = 340,
n = 296 (87%)]
Aged > 65.1 years
[N = 324,
n = 243 (75%)]
NIHSS score of > 6.5
[N = 89,
n = 50 (56%)]
Frequency of ≤ 6.25
per day
[N = 191,
n = 129 (67%)]
Frequency of > 6.25
per day
[N = 133,
n = 114 (86%)]
Amount ≤ 21 – 25
(minutes)
[N = 154,
n = 111 (72%)]
Amount > 21 – 25
(minutes)
[N = 37,
n = 18 (49%)]
Amount ≤ 10.5 per
(minutes)
[N = 91,
n = 56 (61%)]
Amount > 10.5 per
(minutes)
[N = 63,
n = 55 (87%)]
FIGURE 15 CART3. Further exploration of terminal node one from CART1 (NIHSS score of ≤ 7.5, aged ≤ 76.3 years).
This CART investigates associations between dose characteristics, patient characteristics and treatment with
favourable outcome (mRS score of 0–2). Each box shows the number (N) with the headline characteristic plus the
number of them (%, highlighted in bold) with a favourable outcome (mRS score of 0–2). Variables include TTFM,
median daily number of out-of-bed sessions per day (frequency) and median daily out-of-bed activity time
(amount), age, baseline NIHSS, stroke type and rtPA treatment. Note: the ‘training’ and ‘testing’ ROC results were
0.68 and 0.60, respectively. Relative importance of each characteristic: frequency (100%), NIHSS score (99%), daily
amount (84%), age (83%), infarct/haemorrhage (10%), TTFM (4%) and VEM group (3%). CART3 indicates that
higher frequency and lower amounts are important splitters in the model. Adapted with permission from
Bernhardt et al. (2016).33 Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of
the American Academy of Neurology. This is an open access article distributed under the terms of the Creative
Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
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The subgroup analyses of the primary outcome (alive and independent at 3 months) and secondary
outcome (death at 3 months) are outlined in Figures 10 and 11. The UK results were indistinguishable
from those of Asia and Australia and New Zealand, with none of the regional subgroups achieving a
statistically significant level of interaction (p > 0.05).
Economic analysis
An economic analysis was not funded in the context of this NIHR grant. The economic analysis plan34 had
anticipated further analysis would be important in the event of the VEM intervention having a positive
effect. As this was not the case, these analyses are not yet completed.
Meta-analysis of early mobilisation trials
In our systematic review of similar RCTs, we identified eight eligible trials25,27,31,60–64 that currently have data
available. Of these eight trials (2618 participants), AVERT provided the most information (2104 participants).
The median (range) delay to starting mobilisation after stroke was 18.5 (13.1–43) hours in the EM group
and 33.3 (22.5–71.5) hours in the delayed group. The median difference within trials was 12.7 (4–45.6)
hours. Other differences in intervention varied between trials. In at least four trials, the EM group also
received more time in therapy or mobilisation activity.
TABLE 14 Regression analysis for UC group only, showing an association of increased out-of-bed session frequency
and reduced TTFM with the odds of a favourable outcome
Features Favourable outcome OR (95% CI) p-value
Model 1
TTFM (per extra hour of time) 0.98 (0.97 to 0.99) 0.002
Frequency, median daily sessions (per one extra session of
out-of-bed activity)
1.12 (1.04 to 1.21) 0.004
Daily amount, median (per extra 5 minutes of out-of-bed activity) 1.00 (0.93 to 1.07) 0.942
Model 2
TTFM (per extra hour of time) 0.98 (0.97 to 0.99) 0.002
Frequency, median daily sessions (per one extra session of
out-of-bed activity)
1.15 (1.06 to 1.23) 0.0001
Total amount (per extra 5 minute minutes of out-of-bed activity
over intervention period)
0.98 (0.98 to 0.99) 0.001
For every 5-minute reduction in total amount spent in out-of-bed activity there was a significant increases in the odds of a
favourable outcome (model 2). These findings are consistent with those reported for the whole group (see Table 12) and
confirm the important association of frequency on achieving a favourable outcome.
All analyses are adjusted for age and baseline stroke severity (NIHSS). Favourable outcome =mRS score of 0–2.
Model 1 examines the association of TTFM, median daily session frequency and an extra 5 minutes per day with a
favourable outcome.
Model 2 examines the association of an extra 5 minutes over the intervention period (up to 14 days or discharge,
whichever is sooner) with the odds of a favourable outcome.
Frequency is derived from nursing and physiotherapist data and amount (minutes) is derived from physiotherapist data only.
Adapted with permission from Bernhardt et al. (2016).33 This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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Complete 3-month outcome data were available for 2542 (97%) participants (Figure 17). Compared with
delayed mobilisation, EM showed non-significant increases in the odds of death or dependency (OR 1.10,
95% CI 0.94 to 1.29), death (OR 1.27, 95% CI 0.95 to 1.70) and a decreased odds of experiencing any
complication (OR 0.89, 95% CI 0.73 to 1.08).
Repeating the analysis using a random-effects model did not alter these conclusions. There was substantial
heterogeneity of intervention but the average TTFM was not significantly related to the odds of death or
dependency or death alone (test for subgroup differences was p = 0.35 and p = 0.19, respectively).
Figure 17 shows the number (events) with death or poor outcome (mRS score of 3–6) at 3 months after
stroke of the total number of patients (total) allocated to the EM (experimental) or delayed (control)
mobilisation group. Results are presented as the OR (95% CI) of the early versus delayed mobilisation group.
0.2 0.5 1.0
OR
M–H, fixed, 95% CIStudy Events
2.0 5.0
Favours EM Favours delayed mobilisation
Total Events Total
Sundseth65
Bernhardt35
AVERT31
Chippala60
Chippala63
Poletto61
Herisson62
Langhorne27
17
23
558
12
8
8
15
4
27
38
1038
40
24
16
63
16
12
23
520
18
12
8
17
9
29
33
1045
40
25
17
75
16
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FIGURE 17 Meta-analysis of EM trials: early vs. delayed mobilisation in acute stroke patients. df, degrees of
freedom; M–H, Mantel–Haenszel.
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Chapter 5 Discussion
This project met its initial objectives of effectively delivering our VEM protocol with a resulting change inpractice.30 We observed earlier, more frequent and higher dose (amount of) out-of-bed mobility in terms
of sitting, standing and walking activity. However, the unexpected feature was that the VEM intervention
reduced the odds of a favourable outcome at 3 months after stroke compared with lower-dose UC, which
started, on average, 5 hours later. It should be recognised that the outcome of this trial was observed
against a background of a very high level of recovery overall. Despite having more than one-quarter of
participants aged > 80 years and almost half recording a moderate or severe stroke, almost 50% had a
favourable outcome in terms of independence at 3 months. Across both groups, the case fatality rate
averaged only 8%. A further point to note is that HRQoL did not differ significantly between groups at the
12-month follow-up.
The prespecified subgroup analysis raised the possibility that patients with more severe stroke and those
with intracerebral haemorrhage may do less well with VEM, but there was no statistically significant
interaction across these subgroups. Exploration of case fatality within subgroups also suggested the
possibility that intracerebral haemorrhage patients may be at higher risk of harm, but these analyses had
wide CIs and were not statistically significant. Although the trial was not powered to detect differences
between subgroups, these apparent differences may raise potentially important questions and warrant
further investigation. In particular, there have been concerns10,23,24,32,64 about the safety of VEM in frailer
individuals (older patients and those with intracerebral haemorrhage). It is notable that patients receiving
tissue plasminogen activator had outcomes that were similar to those who did not receive this treatment,
hence there is no evidence that EM is particularly harmful in the context of thrombolysis.
The results of this trial are intriguing particularly because the results of smaller trials suggested that early,
frequent and higher-dose VEM would result in a favourable outcome.25–28 A favourable outcome for the
VEM group was also observed in a similar pilot trial in the UK27 and in an individual-patient meta-analysis
of two small EM trials.28 However, a non-significant increase in unfavourable outcome was reported in a
more recent small Norwegian trial65 comparing VEM (< 24 hours) versus later mobilisation (> 24 hours).
It is not yet clear if the results of the current AVERT are simply providing greater precision around these
smaller estimates or if there is some qualitative difference in the nature of the intervention.
We were surprised to observe the very low rates of AEs overall and, in particular, the low rates of
immobility-related complications. We had anticipated that VEM would result in fewer immobility-related
complications but there were no statistically significant differences between groups. One explanation could
be that UC now includes a sufficiently early onset of mobilisation, which may have reduced the risk of
immobility-related complications compared with historical comparisons. The modern high-quality stroke unit
care in the hospitals taking part in AVERT included 75% of patients undergoing out-of-bed mobilisation
within 24 hours and only 7% of patients remaining in bed for > 48 hours. It is striking that UC in the
present trial (median TTFM of 22 hours) was substantially lower than in previous studies (> 30 hours).
Unfortunately, we do not have access to directly comparable information from other acute stroke trials.
The AVERT is, to our knowledge, the largest acute stroke rehabilitation trial to date with a complex
intervention provided by existing clinical staff. Our aim had been to undertake a trial that met the exacting
quality standards of a drug or device trial but that was sufficiently inclusive to be relevant to routine practice.
We achieved our aim of high intervention fidelity and complete primary end-point follow-up in > 99% of
participants. We also succeeded in careful characterisation of the intervention and UC and successfully
adjudicated a large number of safety outcomes. We aimed to enhance the external validity of the trial by
establishing it within routine hospital care across five countries. For these reasons, we believe the results of
the trial are robust and provide important new evidence. The detailed description of the dose characteristics
allowed us to proceed with an exploration of the interaction between intervention and outcome.
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Exploratory analysis
The prespecified exploratory analysis found a consistent association between the odds of recovery with
independence (mRS score of 0–2) at 3 months and some intervention characteristics. These were irrespective
of treatment group and were independently seen in the control group as well as in the combined group
analysis. The odds of a favourable outcome increased with mobilisation frequency: by 13% with each
additional session per day of out-of-bed activity. In contrast, an increasing amount of time spent in out-of-bed
activity was associated with a reduced odds of a favourable outcome when keeping constant intervention
frequency and TTFM. The same pattern of potential beneficial effect with increasing the frequency (but not
the amount) of out-of-bed activity was seen consistently across most of the clinical and safety analyses.
The purpose of these prespecified analyses was to unpack the primary results of the VEM intervention,
which was essentially complex in nature.66 The VEM intervention was defined in terms of TTFM but also
included more frequent and higher-dose out-of-bed activity. The dose–response analysis suggests that
increasing the frequency of mobilisation may help reduce disability and immobility while, in contrast,
increasing the total time of out-of-bed activity in the early phase after stroke was associated with poorer
outcomes. In summary, the exploratory analyses indicate that short, frequent sessions may be preferable
for many stroke patients early after stroke.
The potential impact of TTFM was less clear probably because of a relatively compact distribution of this
variable; therefore, the optimal time to commence out-of-bed activity is still uncertain. Animal studies have
suggested that very high-dose training in the early post-stroke phase may increase brain lesion volume,67
but were not associated with the behavioural outcomes that are analogous to disability measures.
However, conflicting results have also been reported in which moderate exercise reduced lesion volume
and protected ischaemic tissue against secondary damage.68–70
The conventional multivariable analysis was supplemented with the CART analysis. This was to provide an
independent exploration using methodology based on different assumptions. Even when we included patient
characteristics that strongly predict outcome after stroke, such as age and stroke severity, the intervention
characteristics had an important role in defining patient groups. In particular, in patients with more severe stroke
(NIHSS score of > 13), more frequent mobilisation sessions were associated with a more favourable outcome.
Particular strengths of this exploratory study are that the dose–response analysis was prespecified in the
expectation that we would need to explore the intervention in greater detail. One potential criticism of the
exploratory analysis is the possibility that the intervention protocol could have influenced our findings
because the intervention dose was titrated to stroke severity and patients with less severe stroke would
get a higher intervention dose. However, to exclude this possibility we repeated the analysis within the
UC group alone and found the same relationship between TTFM, mobilisation frequency and the amount
of time in mobilisation. In particular, when you maintain mobilisation time and the median minutes of
out-of-bed activity is constant, more frequent sessions in the control group were associated with an
improved odds of a good outcome of 1.12 (95% CI 1.04 to 1.21; p = 0.004). Table 12 outlines the
association between TTFM and a marginally improved outcome and the lack of association between total
amount of out-of-bed activity and outcome. Although the intervention protocol may have provided some
confounding of the observed associations, it cannot explain all the findings observed. The key observations
from the exploratory analysis are as follows:
1. Mobility interventions embedded within routine care and delivered in the acute phase can influence a
patient’s long-term outcomes. It is very important that triallists carefully define and measure these
aspects of care.
2. The generally accepted philosophy that more practice is always better requires reconsideration
particularly early after stroke.
3. The frequency of mobility may be more important than other aspects of delivery. This requires
further investigation.
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
Strengths and limitations
We found that using a screening log that captured a broad range of reasons for non-recruitment added to
the collection of demographic data.38 Similarly, the use of a model to explicitly explore generalisability was
informative. However, a large screening log can collect only a limited amount of demographic and clinical
information and it is quite possible that other factors influenced our recruitment.
The AVERT is largest acute stroke rehabilitation trial with a complex intervention provided by existing
clinical staff. We achieved our aim of undertaking a trial that met the exacting quality standards of a drug
or device trial but that was relevant to routine practice. It was established within routine hospital care
across five countries. We achieved complete primary end-point follow-up in > 99% of participants and
successfully adjudicated a large number of safety outcomes. For these reasons, we believe that the results
of the trial are robust and provide important new evidence.
We believe that we achieved our aim of high intervention fidelity (the extent to which staff adheres to
treatment protocols). This is a challenging part of trials of a complex intervention.66 Within AVERT, sites
were monitored on their delivery of VEM and UC and successful delivered differences in the intervention.36
We provided trial protocols to treating staff who were trained in protocol intervention. Site initiation
sessions were used to discuss and resolve local barriers and we provided reminders, decision tools and
ongoing support for queries. The use of site champions and arrangements such as coleadership from a
nurse and a physiotherapist were seen to be positive factors. It seems advisable that trial protocols for
complex interventions include an implementation plan with the approach that would be used to achieve,
measure and monitor acceptable fidelity standards. We also succeeded in careful characterisation of the
VEM intervention and UC. Establishing fidelity provides confidence that the intervention was properly
tested and that the outcome results can be correctly attributed to the intervention.
Despite these efforts, it is notable that UC TTFM had changed over time (but not the other aspects of
mobilisation, frequency and total time of out-of-bed activities). Although UC was not standardised, careful
trial monitoring allowed tracking of UC over time and provided reassurance that time to start mobilisation
differences between groups were maintained. Mobilisation dose did not change over time. Although the
reasons for earlier UC TTFM over time are unclear, it remains possible that many staff assumed that
commencing earlier was safe and/or effective, and this unconsciously influenced their delivery of UC over
time. External influences include more recent recommendations in clinical practice guidelines to mobilise
early and intensively.
The AVERT has several limitations which are largely due to the large study size. In a large international
trial it is difficult to collect more than a small amount of information about potential modifying or confounding
factors such as physiological variations. It was also difficult to collect detailed information about staff–patient
interactions. As AVERT was a pragmatic trial, we were not prescriptive about UC and it is interesting to note
that TTFM appeared to change substantially during the period of the trial. This occurred despite independent
monitoring, reporting and feedback to the study sites about the nature of their UC and VEM. As a result of
the changes in standard mobilisation practice, by the end of the trial approximately two-thirds of patients
receiving UC had started out-of-bed activity within 24 hours of stroke onset. It is uncertain if this change is a
consequence of contamination from the trial protocol or the result of changing attitudes to EM over time,
as was reflected in some recent clinical guidelines.
Comparison with other trials
Our systematic review was dominated by AVERT but confirmed that EM (within 48 hours) was not
associated with improved outcomes compared with delayed mobilisation. However, it should be noted that
in the majority of trials included in the review, mobilisation commenced within 48 hours of stroke onset
rather than 24 hours. Furthermore, it is important to recognise that despite public education efforts to
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improve identification of stroke and seek early medical attention, patients are often delayed in reaching
hospital. Generally, discussion of the timing of commencement of mobilisation is relative to time of
admission which may be significantly later than time of stroke onset. All AVERT data are relative to time of
stroke onset. In view of the complexity of the intervention and the uncertainty around the effect estimates,
more detailed analyses are warranted.
Implications for practice
Delivery of AVERT required commitment to delivering a VEM intervention that needed strong
interdisciplinary collaboration between nurses and physiotherapists and some modification of current care
models. The qualitative analysis contributed some unique insights into what factors may be important to
successful teams aiming to deliver a complex multidisciplinary intervention.
The results of AVERT should influence clinical practice. Most clinical practice guidelines had recommended
EM10 but there was little specific advice provided. We would conclude that our high-dose frequent
mobilisation protocol within 24 hours of stroke onset was less effective than UC and should not be
routinely applied. However, because the UC protocol is also complex in nature, and increasingly featured a
shift to early onset mobilisation, then it is over-simplistic to simply advise UC. When mobilisations are
attempted early after stroke, short, frequent mobilisations are associated with better outcomes. Further
exploration of this data set is essential and, as outlined in our published statistical analysis plan, we
propose further dose–response analyses to explore the effect of dose rehabilitation on clinical and
safety outcomes.
Implications for research
The AVERT results challenge several previous assumptions and raise several important research questions
that can be listed as follows:
1. What should mobilisation entail: are there aspects that can safely be implemented?
2. Who should we target for early intervention? In particular, are there patient groups for whom EM is
safe or unsafe?
3. Are important physiological and molecular changes induced by early physical activity in ischaemic
tissue? In particular, does early active mobilisation induce early neurological changes that are
detrimental to recovery?
4. How do we best describe the characteristics of EM? We still lack a clear and widely accepted descriptive
framework for EM activities.
The AVERT group are planning a new trial to unpack the combined influences of mobilisation frequency
and dose (duration).
A more detailed meta-analysis of existing trials is also needed to explore the limitations of the AVERT
results in the context of other similar trials.
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Appendix 1 Project outputs
Publications
The main aspects of this project have already been published.
Bernhardt J, Lindley RI, Lalor E, Ellery F, Chamberlain J, Van Holsteyn J, et al. on behalf of the AVERT
Collaboration Group. AVERT2 (a very early rehabilitation trial, a very effective reproductive trigger):
retrospective observational analysis of the number of babies born to trial staff. BMJ 2015;351:h6432.
The AVERT Trial Collaboration Group. Efficacy and safety of very early mobilisation within 24 h of stroke
onset (AVERT): a randomised controlled trial. Lancet 2015;386:46–55.
Bernhardt J, Raffelt A, Churilov L, Lindley RI, Speare S, Ancliffe J, et al. on behalf of the AVERT Trialists’
Collaboration. Exploring threats to generalisability in a large international rehabilitation trial (AVERT).
BMJ Open 2015;5:e008378.
Bernhardt J, Churilov L, Ellery F, Collier J, Chamberlain J, Langhorne P, et al. on behalf of the AVERT
Collaboration Group. Pre-specified dose response analysis for A Very Early Rehabilitation Trial (AVERT).
Neurology 2016;86(Suppl. 23):2138–45.
Bernhardt J, Churilov L, Dewey H, Lindley R, Moodie M, Colier J, et al. for the AVERT Collaborators.
Statistical analysis plan (SAP) for A Very Early Rehabilitation Trial (AVERT): an international trial to
determine the efficacy and safety of commencing out of bedstanding and walking training (very early
mobilisation) within 24 h of stroke onset vs. usual stroke unit care. Int J Stroke 2015;10:23–4.
Luker JA, Craig L, Bennett L, Ellery F, Langhorne P, Wu O, Bernhardt J. Implementing a complex
rehabilitation intervention in a stroke trial: a qualitative process evaluation of AVERT. BMC Med Res
Methodol 2016;16:52.
Bernhardt J, Dewey H, Collier J, Thrift A, Lindley R, Moodie M, Donnan G. A Very Early Rehabilitation Trial
(AVERT). Int J Stroke 2006;1(Suppl. 3):169–71.
Bernhardt J, Churilov L, Dewey H, Lindley R, Moodie M, Collier J, et al. for the AVERT Collaborators.
Statistical Analysis Plan (SAP) for A Very Early Rehabilitation Trial (AVERT): an international trial to
determine the efficacy and safety of commencing out of bed standing and walking training (very early
mobilisation) within 24 h of stroke onset vs usual stroke unit care. Int J Stroke 2015;10:23–4.
The AVERT Trial Collaboration group, Bernhardt J, Langhorne P, Lindley RI, Thrift AG, Ellery F, et al. Efficacy
and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial.
Lancet 2015;386:46–55.
Bernhardt J, AVERT investigators. Could upright posture be harmful in the early stages of stroke? -
Author’s reply. Lancet 2015;386:1734–5.
Bernhardt J, Lindley RI, Lalor E, Ellery F, Chamberlain J, Van Holsteyn J, et al. on behalf of the AVERT
Collaboration Group. AVERT2 (a very early rehabilitation trial, a very effective reproductive trigger):
retrospective observational analysis of the number of babies born to trial staff. BMJ 2015;351:h6432.
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Bernhardt J, Churilov L, Ellery F, Collier J, Chamberlain J, Langhorne P, et al. on behalf of the AVERT
Collaboration Group. Pre-specified dose response analysis for A Very Early Rehabilitation Trial (AVERT).
Neurology 2016;86(Suppl. 23):2138–45.
Sheppard L, Dewey H, Bernhardt J, Collier JM, Ellery F, Churilov L, et al. on behalf of the AVERT Trial
Collaboration Group. Economic Evaluation Plan (EEP) for A Very Early Rehabilitation Trial (AVERT): an
international trial to compare the costs and cost-effectiveness of commencing out of bed standing and
walking training (very early mobilization) within 24 hours of stroke onset with usual stroke unit care. Int J
Stroke 2016;11(Suppl. 4):492–4.
Conference presentations
There have been a large number of conference presentations (> 30) by various members of the AVERT
team. These included European Stroke Organisation Conference 2015 and 2016, International Stroke
Conference 2015, 2016, Stroke Society of Australia 2014–16, and the UK Stroke Forum 2014–15.
Presentations to investigators, professional associations and UK
stroke network
A large number of local and regional presentations were carried out and have been reported in the
investigators newsletters. This has included presentations at the UK Stroke Forum (2011, 2012, 2013,
2014), local meetings (March 2013, April 2013, European Stroke congress 2013). In addition, we hosted
two large UK contributor meetings in Glasgow in October 2013 and April 2015.
Consumers
We have disseminated the 3-month results for distribution from each hospital to the patients recruited.
After the 12-month results are published, patients will be allowed to find out what group they were in
(from the local hospital) and we will publish a final patient report. Alongside this, we plan to disseminate
results to consumers via consumer organisations [e.g. the Stroke Association (UK) and the National Stroke
Foundation (Australia)].
Media/social media
We have promoted and publicised the trial on social media [Twitter (www.twitter.com; Twitter, Inc.,
San Francisco, CA, USA), Facebook (www.facebook.com; Facebook, Inc., Menlo Park, CA, USA) and blogs].
Clinical guidelines
Two stroke clinical practice guidelines (USA,71 Canada72) have recently changed. Updates of the UK73 and
Australian74 guidelines are underway.
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Clinical trials websites
The NIHR HTA and AVERT websites are up to date, with grant publications online. www.nets.nihr.ac.uk/
projects/hta/120116 (accessed 28 August 2017).
www.gla.ac.uk/researchinstitutes/icams/staff/peterlonghorne/#/grants,researchinterests
(accessed 28 August 2017).
www.florey.edu.au/very-early-rehabilitation-trial-avert (accessed 28 August 2017).
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Appendix 2 Participating sites
Hospital site Numbers recruited Principal investigator
Australia 1043
Austin Hospital 253 H Williamson
Royal Perth Hospital 149 J Ancliffe
Royal Melbourne Hospital 95 L Werner
Frankston Hospital 90 L Sundararajan
Westmead Hospital 84 R Chen
Geelong Hospital 74 R Sheedy
Alfred Hospital 42 K Richardson
Flinders Medical Centre 40 S Choat
Western Hospital 37 T Wijeratne
Albury Hospital 23 V Crosby
Epworth Hospital, Richmond 23 S Gerraty
St George Hospital 23 M Tinsley
Nambour Hospital 20 D Rowley
Warrnambool Hospital 15 P Groot
Sir Charles Gairdner Hospital 15 L Cormack
St Vincent’s Hospital 12 W Zhang
West Glippsland Hospital 12 S Smith
Wyong Public Hospital 11 G Auld
The Wesley Hospital 9 J Cramb
Calvary Mater Newcastle 8 A Robertson
Wodonga Hospital 8 L Tighe
Belmont Hospital 5 M Spear
Wollongong Hospital 4 C Tse
Gosford Hospital 2 P Andersen
New Zealand 189
Auckland Hospital 189 G Wavish
Singapore and Malaysia 251
Singapore General Hospital 128 S Hameed
UKM Malaysia 123 MA Katijjahbe
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Hospital site Numbers recruited Principal investigator
UK 610
Forth Valley Royal Hospital 65 M Macleod
Yeovil District Hospital 61 D Neal
York Hospital 54 M Keeling
Royal Victoria Infirmary 35 S Louw
Aberdeen Royal Infirmary 33 MJ Macleod
Royal Bournemouth 32 K Saunders
Imperial College Hospital (St Marys) 29 P Meakin
Wishaw General Hospital 28 S Kirk
Monklands Hospital 26 M Barbour
Ulster Hospital 25 B Wroath
Royal Devon & Exeter Hospital 23 C Charnley, et al.
Queen Elizabeth The Queen Mother Hospital 21 J Sampson, et al.
Antrim Area Hospital 18 D Mullan, et al.
Wansbeck General Hospital 18 C Price, et al.
Blackpool Hospital 17 V Green
North Tyneside General Hospital 17 L Mokoena, et al.
Belfast City Hospital 15 S Tauro, et al.
Harrogate District Hospital 15 S Brotheridge, et al.
St Mary’s Hospital Isle of Wight 13 T Norman, et al.
Nevill Hall Hospital 12 K Buck
Western Infirmary 10 M Walters
South Tyneside District Hospital 8 H Hunter
Calderdale Royal Hospital 7 A Nair
London St George Hospital 7 G Cloud
North Devon District Hospital 6 R Latif, et al.
Royal Infirmary Edinburgh 6 T Elder-Gracie, et al.
Hexham General Hospital 5 K Robinson
Crosshouse Hospital 3 K Mason
Daisy Hill 1 C Douglas
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Appendix 3 Protocol version 3
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